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Abstract
Our studies aim to establish an all-purpose system, in which one type
of implant can be used for every patient, due to an independent loading
concept, whereas drug dose and type are individually adaptable. Biocom-
patible, biodegradable polymer beads can be charged with a large number
of different therapeutics. The implant itself will be camouflaged with a
polymer layer, that should be optimised for tissues located in the implant
environment. Furthermore this layer will be derivatised chemically to
contain specific binding pockets for the drug loaded biodegradable nano
particles.
A method for quantification of such binding sites is needed. Different ap-
proaches have to be evaluated regarding amount, stability and specificity
of the immobilised binding sites.
Zusammenfassung
Das Ziel dieser Untersuchung ist ein “Drug Targeting System” zu ent-
wickeln, bei welchem ein Implantattyp universell einsetzbar ist. Ein
unabha¨ngiges Ladekonzept, wobei Dosis und Art der Medikation indi-
viduell justierbar sind, soll dem Rechnung tragen. Biokompatible, bioab-
baubare Polymerbeads ko¨nnen mit einer großen Anzahl an unterschied-
lichen Therapeutika beladen werden. Das Implantat soll mit einer Poly-
merschicht u¨berzogen werden, welche fu¨r das umliegende Gewebe op-
timiert ist. Weiters soll diese Schicht spezifische Bindestellen fu¨r die
medikamentbeladenen abbaubaren Nanopartikel besitzen, welche durch
chemische Derivatisierung eingebracht werden.
Es soll ein Methode zur Quantifizierung solcher Bindestellen entwickelt
werden. Verschiedene Ansa¨tze mu¨ssen evaluiert werden im Hinblick auf
Anzahl, Stabilita¨t und Spezifita¨t der immobilisierten Bindestellen.
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Chapter 1
Introduction
Once upon a time there was a German chemist, physician, immunologist
and serologist named Paul Ehrlich. Over a hundred years ago he founded
the concepts of chemotherapy when he declared:
Eine wesentliche Aufgabe ... wird es sein, Substanzen und
chemische Gruppierungen aufzufinden, welche eine besondere
Verwandschaft zu bestimmten Organen besitzen (organotrope
Stoffe). Von besonderer Wichtigkeit wird es aber sein, solche
gewissermaßen als Lastwagen fungierende Substanzen mit che-
mischen Gruppierungen von pharmakologischer oder toxiko-
logischer Wirkung zu versehen, so daß sie gleichzeitig die
ihnen anvertraute Last an die geeigneten Stellen befo¨rdern. [1]
In other words this means: A main challenge will be to find substances
and chemical groups, which have a particular relation to certain organs. It
will be of outstanding importance to supply trucks with pharmacological
or toxicological effective substances, so that they can carry their payload
to the appropriate location.
Theophrastus Paracelsus already believed that drugs must have barbs
(spicula), so that they can attach on destined organs. In terms of chemistry
these spicula are chemical groups with affinity to those organs. Ehrlich
drew the picture of a poison arrow. The arrowhead (spiculum) is a hap-
tophore group that binds to its target (chemical receptor on the cell surface).
Due to the reason that a haptophore does not necessarily have a therapeu-
tic effect it should be combined with a drug molecule, similar to an arrow
poison [2].
Now this is exactly what modern drug targeting approaches are about.
1
1.1 Drug targeting principles
In general there are four categories of drug targeting principles:
• Direct application of drugs
• Spontaneous drug accumulation in leaky areas
• Physical targeting
• Targeting with high affinity vector molecules
These principles will be discussed in a brief manner. The method of tar-
geting with high affinity vector molecules is the topic of the following
sections.
Direct application
Sometimes it is possible to directly administer a drug into an affected
area. Williams et al. showed that a single intra-articular injection of a
liposomal hormone conjugate is effective in the treatment of arthritis in a
rat model [3]. However such approaches will be successful only in a clearly
localized area, where the drug is retained for an adequate time. Actually
this is not the case in most diseases, so that commonly this method is not
usable.
Spontaneous drug accumulation
The most important mechanism of spontaneous drug accumulation is the
enhanced permeability and retention effect (EPR-effect) [4]. Due to a lack
Figure 1.1: The EPR effect [5]
of nutrients and oxygen tumours cannot grow much larger than two mm3
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in size, so they have to secret growth factors for angiogenesis. These
capillaries have an abnormal shape. Furthermore solid tumours have
an elevated level of vascular permeability factors [6]. Macromolecules and
liposomes can permeate the leaky vasculature and with a molecular weight
over 50 Kilo Dalton (kD), they are retained there for a longer period than
in normal tissue [7].
Physical targeting
Physical parameters such as temperature or pH can be used for drug target-
ing. Inflamed tissue or tumours for example show a higher temperature,
due to an increased blood stream in that region. Weinstein et al. developed
drug loaded thermosensitive liposomes. The released drug accumulated
several times faster in tumours. The effect could be enforced by external
heating of the targeted area [8].
Another attractive example for physical targeting is drug conjugation with
magnetic nano particles. They are retained in the targeted area with a
magnetic field. Munnier et al. combined doxorubicin (anthracycline an-
tibiotic used in cancer chemotherapy) with Super Paramagnetic Iron Oxide
Nano Particles (SPIONs). They could show that the released doxorubicin
exhibits a cytotoxic activity at least as high as that of a pure drug solu-
tion, with the additional advantage of local accumulation by an externally
applied magnetic field [9]. Recently a SPION aerosol was established and
tested in vivo (mouse). After inhalation an eight fold increase in SPION
concentration was observed in the lobe subjected to an external magnetic
field as compared to the opposite lobe. By extending the distance between
the thorax wall and the magnet from one to two mm, the relative SPION
accumulation decreased from eight to 2.5 [10]. The fact that the magnetic
field decreases in distance might limit the benefits of this concept in hu-
mans simply because of the bigger organ sizes of humans compared to
those of mice.
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Targeting with high affinity vector molecules
This is the most promising effort to overcome the issues of drug thera-
pies. The concept is already realised in some of the most powerful toxins
known today, e.g. botulinum toxin, diphtheria toxin. Ehrlich proposed
the mechanism of action referring to the diphtheria toxin:
We must, therefore, thus represent the action of the poison that
with the help of the haptophore groups, the toxin molecule
becomes ’anchored’ to the cell, and that it comes in this way
within the sphere of action of the toxophore group. [11]
Different haptophores are going to be discussed in the following sections.
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1.2 Monoclonal antibodies
Usually an antibody or Immunoglobulin (Ig) consists of two heavy (H)
and two light (L) amino acid chains. In higher vertebrates there are five
classes of antibodies, respectively the five different types of H chains.
Table 1.1: Antibody classes (subclasses)
Ig class H chain Structure
IgA1 ; IgA2 α1 ; α2 dimer
IgD δ monomer
IgE  monomer
IgG1, IgG2, IgG3, IgG4 γ1, γ2, γ3, γ4 monomer
IgM µ pentamer
Figure 1.2: Schematic view of an IgG antibody1
The majority of antibodies used
in therapy are of the IgG class,
in which two identical H chains
combined with two identical L
chains (of the κ or λ class) form
a IgG with an Y like shape. The
H and L chains are sub classi-
fied in constant (C) and variable
(V) regions. The amino termi-
nal ends of the variable regions
of the heavy and light chain (VH
and VL) form the antigen binding
pocket, whereas the constant re-
gions of the H chain (CH) dictate
the biological function of the anti-
body.
Furthermore there are three stretches of approximately ten amino acids
in length within the VH and VL chains with an unusually high variability.
They are termed the complementary determing residues that make con-
tact with the antigen determinant [12]. The rest of the variable fragments
1From Encyclopaedia Britannica http://www.britannica.com/EBchecked/topic-
art/27988/107006/The-structure-of-an-antibody-molecule-represents-the-dramatic-
rearrangements
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Figure 1.3: Space-filling view of a human IgG1 molecule. One H chain is in white and the
other is dark gray; the two L chains are lightly shaded. The black spheres represent the
complex carbohydrate [15].
are relatively constant and are building the framework regions.
The three dimensional structure of a whole antibody molecule was elu-
cidated in 1967 by x-ray diffraction [13]. The theoretical model of a key
(antigen) that fits exactly in just one lock (antibody) was used to explain
the specificity of antibodies. But when the antibody binds the antigen struc-
tural rearrangements can occur in both of them. The interaction therefore
has more the character of a handshake than that of the “lock and key”
model [14].
In the beginning the whole antisera from immunised animals were used.
Thereby different B-cells are producing different antibodies against dif-
ferent epitopes of an antigen. But with the development of monoclonal
antibodys (mAbs) in 1975 by Ko¨hler and Milstein2 the revolution had be-
gun. A mouse myeloma cell line was fused to spleen cells of an immunised
mouse according to the method of Harris and Watkins using a Sendai virus
strain [16]. The myeloma cells had a specific resistance and were not able to
grow on selective media. Furthermore they could not secrete full antibody
chains, whereas the spleen cells where able to grow on the selective media
and produced healthy antibodies towards the antigen used for immunisa-
2Nobel Price award in Physiology or Medicine in 1984 along with N.K. Jerne: ”For
theories concerning the specificity in development and control of the immune system and
the discovery of the principle for production of monoclonal antibodies”
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tion. Hence they were able to select only for fused cells (hybridoma cells)
with the potential of immortality (from the myeloma cell) and production
of antigen specific antibodies (from the spleen cells) [17].
The secreted antibodies derive from a single B-cell and are therefore termed
monoclonal antibodies. Now these mAbs are more similar to a homing
missile than to a simple arrow head and are approaching Ehrlich’s vision
of the magic bullet.
1.3 Production of monoclonal antibodies
For a long time the standard method for mAb production consisted of
an in vivo immunisation and an in vivo production. At the end of the
immunisation period the animal is sacrificed and antibody producing cells
are harvested from the spleen. Now these cells are fused to myeloma
cells and selected for specificity. Then the desired mAbs are produced
by ascites induction, i.e. priming of the animal (with pristan or IFA)
followed by intraperitonal injection of the hybridoma cells. After one to
three weeks the ascites fluid is removed, containing a mAb concentration
up to 28 mg/ml [18].
The first in vitro immunisation was performed by Hengartner et al. in
1978 [19]. Nowadays kits are available for this procedure. The advantages
to in vivo immunisations are:
• Fast production of mAbs, i.e. a few days compared to weeks with
the in vivo method.
• Very small amount of antigen is needed.
• The immune response is not subject to the usual control mechanisms
which apply to self antigens and weak antigens [20].
The most important fact is that one is not legally obligated to produce
mAbs from an animal origin because human lymphocytes might be used
as well in the process [21].
The in vitro production of mAbs requires some skills in cell culture. The
hybridoma cells can be cultivated in a Tissue culture flask (TCF), per-
meable gasbag or in a more elaborate approach by using a Hollow fibre
cartridge (HFC). In the first two production methods the cells have to
be adapted to growing in serum free media to avoid contamination with
bovine antibodies, whereas in the HFC approach the cells are separated
from media by a semi permeable membrane with a defined Mr cut off.
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Table 1.2: Comparison of different in vitro mAb production methods [22]
Method Disadvantages Advantages
TCF Cells must be adapted to
serum free media, occupies
the most incubator space,
large volumes of media
must be processed
technically easy
Gas perme-
able bags
Cells must be adapted to
serum free media, large
volumes of media must be
processed
Technically easy, occupies
less space then TCF, may
require less media then
TCF
Hollow
fibre
cartridge
Large initial investment,
technically more challeng-
ing, mechanical disruption
or contamination, large
amounts of media ex-
pended
Large yield in a small vol-
ume, culture media may
contain high concentra-
tions of foetal calf serum
1.4 Modification of monoclonal antibodies
Due to their murine origin, mAbs showed a high immunogenicity in clini-
cal treatment [23]. In the mid eighties the first chimeric antibodies were gen-
erated with recombinant DNA technologies to overcome these issues [24–26].
They consisted of the murine Fab part that was conjugated to a human Fc
antibody fragment. Lo Buglio et al. showed that these chimeric mAbs have
an increased circulation time in humans, i.e. six times as long as murine
Immunoglobulin G (IgG) but only one-fifth as long as human IgG [27].
The next step towards a more human mAb was performed by Riechmann
et al. in 1988. The idea was not to conjugate the whole Fab part to a human
Fc fragment, but to transplant only the antigen binding sites (i.e. the hyper
variable or complementary determing regions from rodent origin in this
case). Given that the sequences of the hyper variable regions do not con-
tain characteristic rodent or human motifs, these “reshaped” mAbs should
be indistinguishable from human antibodies [28].
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Figure 1.4: Structure of a mAb and modifications of a murine mAb [29]
As a last conclusion this trend in antibody modification led to the genera-
tion of fully human mAbs. Different approaches reach the goal:
• In vitro immunisation of human lymphocytes (mentioned earlier in
this section)
• mAb production in transgenic mice
• mAb production using phage display technologies
The mAb production with human lymphocytes has proven to be very dif-
ficult. The fusion of these cells to murine myeloma cell lines resulted in
preferential loss of human chromosomes. Moreover the hybridoma cells
are unstable [30].
Lonberg et al. created transgenic mice, which are able to express human
antibodies [31]. They selected hybridoma cells secreting human mAbs with
binding constants in the range of corresponding murine mAbs already
used in clinical trials. In 2007 the first human mAb (Panitumumab3) pro-
duced with such transgenic mice (XenoMouse system4) was approved for
the clinical treatment of advanced colorectal cancer [32].
3Human anti-EGFR mAb
4Transgenic mice with inactivated mouse antibody production machinery replaced by
the human Immunoglobulin heavy and light chain loci
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1.4.1 Antibody digestion and creation of scFv
If the antibodies are used only for targeting reasons the effector functions
of the constant regions are not needed. Antibodies can be engineered by
protein digestion. For example a digestion with papain produces two Fab’
fragments and one Fc fragment, whereas the digestion with pepsin leads
to one F(ab’)2 fragment and numerous Fc sub fragments.
In a more elaborate approach a single chain Fv fragment (scFv) can be
produced with cloning techniques. A scFv consists of the VL and the
VH fragments linked by a polypeptide chain that connects the carboxy-
terminal residue of the VL domain with that of the amino terminus of the
VH domain [33]. The genes encoding the domains of interest are cloned in
a vector and subsequently expressed in E.coli. The resulting scFv are the
smallest antibody fragments (Mr = 26 kD) that still possess the complete
antigen binding pocket with a similar specificity and affinity as the natural
fragment from which they derive [34].
Figure 1.5: Antibody fragments produced with protein digestion or molecular biology
techniques [35]
1.4.2 Phage display technology
Phage display is a very powerful genetic tool. The idea is to clone a
DNA fragment into a phage coat protein. Now the phage expresses the
protein on its coat surface corresponding to the genetic sequence inside [36].
Mc Cafferty et al. succeeded in expressing a scFv on the surface of a
filamentous fd phage [37]. The phages binding to the antigen were isolated
by a simple affinity chromatography.
Very large libraries can be generated by randomly combining different
heavy and light chain variable antibody fragments [38,39]. In a screen assay
an immobilised antigen is incubated with such a library. Phages with
affinity to the antigen will bind on the surface, whereas the rest is washed
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Figure 1.6: Selecting antibodies from phage libraries [40]. (1) Phages are incubated with
the antigen of interest. (2) Phages that express scFv fragments that do not bind to the
antigen are washed away. (3) Phages that express scFv fragments that bind to the antigen
are isolated, expanded, purified, and used in further applications.
away. Then the bound phages are amplified by infection of E.coli from
whom the scFvs can be isolated for further usage.
1.5 Monoclonal antibodies in clinical trials
In 1986 the first mAb (Muromonab OKT-3 5) [41] was approved by the Food
and Drug Administration (FDA) to treat acute renal rejection in patients
who are resistant to the standard steroidal therapy6. A decade later mAbs
found their way into cancer chemotherapy. Rituximab7 was the first mem-
ber for the treatment of B-cell non Hodgkin’s lymphoma [43]. Today there
are about 3600 ongoing or completed clinical trials including mAbs, which
is about 5% of all registered trials8. These data clearly show how emerging
mAb-therapy has become. Most mAbs are used in cancer therapy, but
also the treatments of autoimmune diseases, transplant rejection, viral and
even bacterial infections, are under investigation.
5murine monoclonal IgG2a antibody that binds to the CD3 complex on T cells, thus
blocking their function
61993 a second indication for Muromonab was approved for the treatment of acute
rejection in heart and liver transplants (http://fda.gov)
7chimeric mAb against CD20 with a human Fc part that can mediate tumour lysis
using human complement or ADCC effector cells [42].
8http://clinicaltrials.gov with 67000 trials registered in 160 countries
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Table 1.3: Monoclonal antibodies in clinical trials
Intervention Targeting antibody Disease
Gavilimomab Murine anti-CD147
mAb
Acute graft versus host dis-
ease
3F8-mAb,
etoposide,
isotretionin
Murine anti-GD2
mAb
Neuroblastoma
Mik-β-1 Murine anti-IL-2R β
mAb
Chronic lymphocytic
leukaemia
Edrecolomab Murine anti-CSGP
17-1A mAb
Stage II colon cancer
CNTO 328 Chimeric anti-IL-6
mAb
Metastatic prostate cancer
Cetuximab, Cis-
platin
Chimeric anti-EGFR
mAb
Metastatic or recurrent
head and neck cancer
Infliximab Chimeric anti-TNF α
mAb
Crohn’s disease
RAV12 Chimeric anti-
RAAG12 mAb
Metastatic pancreatic can-
cer
Fontolizumab Humanised anti-
IFNγ mAb
Crohn’s disease, Colitis, In-
testinal disease
CAL Humanised anti-
PTHrP mAb
Breast cancer metastatic to
bone
HuJ591 Humanised anti-
PSMA mAb
Prostate cancer
ING-1(heMAb) Humanised anti-Ep-
CAM mAb
Advanced adenocarci-
noma
Trastuzumab,
Paclitaxel
Humanised anti-
HER2 mAb
Recurrent or metastatic
breast cancer
Lintuzumab,
cytarabine,
etoposide,
mitoxantrone
Humanised anti-
CD33 mAb
Acute myelogenous
leukaemia
HuM291 Humanised anti-CD3
mAb
Advanced or recurrent
lymphoma
Hu3S193 Humanised anti-
Lewis-Y mAb
Advanced colorectal carci-
noma
Continued on next page
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Table 1.3 – continued from previous page
Name Targeting antibody Disease
HuHMFG1 Humanised anti-
MUC-1 mAb
Locally advanced or
metastatic breast cancer
MRA Humanised anti-IL-
6R mAb
Systemic Lupus Erythe-
matosus
F105 Human anti-gp-120
mAb
HIV infections
CAT-192 Human anti-TGF β1
mAb
Systemic sclerosis, sclero-
derma
Cixutumumab
(IMC-A12)
Human anti-IGF-IR
mAb
Metastatic soft tissue sar-
coma
Adalimumab Human anti-TNF α
mAb
Rheumatoid Arthritis,
Crohn’s disease
Raxibacumab Human anti-BAPA
mAb
Anthrax (tested in healthy
subjects)
Sevirumab Human anti-CMV
mAb
Cytomegalovirus retinitis,
HIV infections
Although some therapies are very promising, it is important to be very
careful, especially in phase I trials (i.e. first test in human subjects).
On March 13 2006 a tragic accident happened at the Northwick Park Hos-
pital in London. Six test persons received an intravenous injection of
TGN1412 antibody9. Two hours after the injection all six volunteers suf-
fered from a cytokine storm leading to headache, backache, nausea, a drop
in blood pressure and finally to multiple organ failure [44].
TGN1412 was developed to treat leukaemia and autoimmune diseases
such as rheumatoid arthritis. It acts as a superagonist that induces the
activation and expansion of immunosuppressive regulatory T cells. Usu-
ally two signals are needed to get this response, but TGN1412 can trigger
it alone. TeGenero performed in vitro and in vivo test with Cynomolgus
Macaques, due to a 100% homology of the CD28 T cell receptor of the
monkeys and humans. No side effects were observed and the drug was
considered safe.
Two possibilities could explain the different in vivo responses in humans
9Humanised monoclonal antibody against the CD28 T cell receptor; developed by
TeGenero Immuno Therapeutics
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and non human primates. The first would be that the magnitude of the
TGN1412 response elicited in monkey T cells is much lower than that in
human T cells (quantitative model). Alternatively, TGN1412 stimulation
of monkey T cells might not activate the same intracellular signalling path-
ways as it does in human cells (qualitative model) and, therefore, might not
induce cytokine synthesis [45]. In addition Stebbings et al. showed that the
monkeys peripheral blood mono nuclear cells do not produce cytokines in
vitro [46].
Much more precaution is now taken in clinical trials involving antibod-
ies and especially immunomodulatory substances, since this day in 2006,
where six healthy test persons almost died.
1.6 More arrow heads or targeting moieties
Monoclonal antibodies are by far the most popular molecules for targeting
approaches. Nevertheless there is a huge pool of other entities who might
be even more effective in solving the issues of drug therapies. Some of
them are discussed in a briefly manner in this section.
1.6.1 Aptamers
Aptamers are small DNA or RNA oligonucleotides who exhibit ligand
binding characteristics. They can be isolated from a large pool of random
sequences somehow similar to phage display technology.
The procedure was developed independently by Ellington et al. and
Tuerk et al. [48,49] :
• In a first step hundred random nucleotides flanked by defined re-
gions for primer binding are made by solid phase synthesis, yielding
approximately 1015 individual sequences.
• The sequences are amplified by Polymerase chain reaction (PCR)
resulting in a final diversity of 1013 sequences.
• Transcription with RNA polymerase.
• Polyacrylamide gel electrophoresis to ensure size homogeneity of the
RNA molecules.
• Affinity chromatography using the target of desire as column mate-
rial.
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Figure 1.7: Generation of aptamers with SELEX [47]
• Reverse transcription to gain the complementary DNA’s.
• Next round of PCR amplification
With every repeated cycle the aptamers with affinity to the column are
enriched. For example Ellington and Szostak reported that less than 1%
of the applied RNA bound to the column in the first two cycles, but in the
fourth round over 50% of the applied RNA was bound.
Now these aptamers have some clear advantages over mAbs including:
• Fast in vitro production through the systemic evolution of ligands by
exponential enrichment (SELEX) process as described above.
• Smaller size of approximately 15 kD
• Lesser immunogenicity
• Because of the in vitro production they can be generated regardless
of the immunogenicity or toxicity of the antigen.
In 1998 Ruckman et al. published a highly sophisticated, nuclease resistant
and pegylated aptamer against the VEGF [50]. It took only six years for this
aptamer, later named pegaptanib (brand name Macugen), to achieve FDA
approvement for the treatment of neovascular (wet) age-related macular
degeneration [51].
For a recent review in the field of aptamers please see Yang et al [52].
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1.6.2 Oligopeptides
Oligopeptides (OPs) might be another promising candidate for drug tar-
geting. OPs consist of very short amino acid chains. In 1984 Geysen et
al. tried to find the immunologically relevant epitope of the coat pro-
tein of foot-and-mouth disease virus. They synthesised every possible
hexapeptide combination from the whole coat protein, immobilised them
and scanned with ELISA. They found out which part (the epitope) of the
coat protein was responsible for antibody interaction with a resolution of
seven amino acids in length. Further amino acid variation of the found
hexapeptide led to the identification of the two most important amino
acids of that epitope [53]. Maybe with this experiment the idea to create OP
libraries and examine their potential binding to a target was born.
Short time later the first libraries were generated either by fusing OPs
• to phages [54–56]
• to a DNA binding domain [57]
• or to polymer beads [58,59]
The process for isolation is similar to that used in phage display technology
(see page 10), only that this time not a whole scFv is fused to the coat protein
of the phage but only a short sequence of about six to fifteen amino acids.
Then again with every panning round followed by amplification the OPs
with affinity to the target can be isolated.
Usually the selection of useful OPs is done in vitro by screening against
purified immobilised targets. But there are some publications that describe
an in vivo screening [60,61]. For example Pasqualini et al. showed that a
cyclic nonapeptide displayed on a phage with affinity to αv integrins was
accumulated very selective in the tumour vasculature after i.v. injection in
mice [62].
Recently Krag et al. expanded this trend in in vivo screenings to humans
with stage IV cancer. They screened two phage displayed OP libraries
along with a scFv library. In the end they were able to identify one targeting
candidate from the OP libraries and six from the scFv library, verifying the
results in an immunostaining experiment. Furthermore no severe side
effects related to the phage injection could be observed during the study
as well as no immune response against the phages did develop during
the first week after administration [63]. The earlier mentioned OP against
the αv integrins10 showed some encouraging results in phase II clinical
10Now in a pentameric cyclic form (L-arg-gly-L-asp-D-phe-L-val) named Cilengitide
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trials. It was well tolerated exhibiting modest anti tumour activity [64]. Now
Cilengitide is going into phase III clinical trial in combination with standard
therapy for subjects with newly diagnosed glioblastoma multiforme11
11The most common and most aggressive brain tumour
17
Chapter 2
Research Objectives
In this work we are developing a new drug targeting system, that might
solve some of the problems such approaches are still confronted with. Usu-
ally implants are not tolerated by the immune system. Some approaches
exist in which a drug is included in the implant to suppress the immune
response. But the drug in this implant type is bleeding out after a short
period, hence losing its beneficials. Therefore we are trying to establish a
reloadable implant surface. Our idea is to mark the target in the patient
(e.g. implant, tumour) with specific binding sites for polymer based drug
vehicles. The polymer beads can bind to the target and release the drug.
The degradation of the polymer should free the binding sites for a further
loading step.
Implant materials (e.g., 316-L stainless steel, ZrO2) are coated with biocom-
patible polymers. Furthermore this layer will be derivatised chemically
to contain specific binding pockets for drug loaded biodegradable nano
particles.
Aims of the thesis
• Development of a method for quantification of the biorecognitive
sites.
• Testing varied methods for chemical antibody processing.
• Evaluation of different bioconjugate techniques, regarding stability
and site direction of the binding pockets.
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Chapter 3
Materials
Table 3.1: Reagents
Empirical Formula Name Provider
CH3COOH Acetic acid, glacial J.T. Baker (6052)
Al2O3 Aluminium oxide 90
neutral
Merck (1.01077.1000)
C9H23NO3Si (3- Aminopropyl) tri-
ethoxysilane
Fluka (09324)
C16H28N4O4S Biocytin Sigma (B-1758)
C10H15N2O3S d-Biotin Sigma (B-4639)
Bisamino PEG Fluka (14529)
C6Cl4O2 Chloranil Fluka (23290)
C9H21ClO3Si (3- Chloropropyl) tri-
ethoxysilane
Sigma (569615-
100ML)
C6H8O7 Citric acid Sigma (C0759-500G)
C3H7NO2S L- cysteine Sigma (C7352-100G)
Na2HPO4 ·H2O Disodium hydrogen
phosphate
Merck (1.06580.1000)
C8H17N3 ·HCl EDC Sigma (E7750-25G)
C10H14N2Na2O8 EDTA Disodium salt Appli. Chem
(A2937,1000)
C14H8N2O8S2 Ellmann‘s reagent Pierce (22582)
C5H8O2 Glutaraldehyde Solu-
tion
Fluka (49626)
Continued on next page
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Table 3.1 – continued from previous page
Empirical Formula Name Provider
HCl Hydrochloric acid,
37-38%
J.T. Baker (6081)
H2O2 Hydrogen peroxide,
30%
Merck (1.07209.0250)
C6H13NO2 L- Leucine Sigma (L8000-25G)
C8H14O2S2 Lipoic acid Sigma (T5625-1G)
MgCl2 ·6 H2O Magnesium chloride
hexahydrate
Riedel de Haen
(31413)
C2H7NS 2- Mercaptoethy-
lamine
Sigma (M-9768)
CH3(OCH2CH2)nOH Methoxy PEG Aldrich (20.250-9)
NiSO4 ·6 H2O Nickel sulphate hex-
ahydrate
Appli. Chem
(A0827,0100)
C9H6O4 Ninhydrin Spray So-
lution
Merck (1.06705.0100)
C6H4NO2PO4H p- Nitrophenyl phos-
phate
Koch Light Ltd.
(93092)
PLGA Aldrich (531154-1G)
KCN Potassium cyanide Merck (4967)
Protein Assay Bio-Rad (500-0006)
CH3COONa Sodium acetate Riedel de Haen
(25023)
NaBH4 Sodium borohydride Aldrich (21,346-2)
Na2CO3 ·10 H2O Sodium carbonate
decahydrate
Riedel de Haen
(31431)
C6H5Na3O7 ·2 H2O Sodium citrate triba-
sic
Riedel de Haen
(32320)
NaH2PO4 ·H2O Sodium dihydrogen
phosphate
Merck (1.06346.1000)
NaCl Sodium chloride Riedel de Haen
(31434)
NaHCO3 Sodium hydrogen
carbonate
Riedel de Haen
(31437)
NaOH Sodium hydroxide Riedel de Haen
(30620)
NaIO4 Sodium periodate Aldrich (31,144-8)
Continued on next page
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Table 3.1 – continued from previous page
Empirical Formula Name Provider
C4H4O3 Succinic anhydride Merck (8.00683.0500)
C16H15N2O9SNa sulfo- SMCC Pierce (22322)
C4H4NO6SNa sulfo- NHS Pierce (24510)
TMB61 HRP sub-
strate
Sciotec
C58H114O26 Tween 20 Sigma (P9416-
100ML)
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Chapter 4
Methods
The methods used in this thesis will be described in a general manner.
4.1 Chromatography
4.1.1 Gel Filtration
Gel filtration or size exclusion chromatography is a fast and simple method
to separate proteins or other macromolecules based on their size (hydro-
dynamic volume). The stationary phase in a gel filtration system consists
of a porous polymer matrix with a well defined pore size. Small molecules
can enter the pores causing retention of the latter, whereas molecules larger
then the pore size elute faster, due to the shorter way they have to travel
through the column.
There is no interaction as usual in chromatography between the stationary
and the mobile phase. Therefore a wide range of mobile phase systems
can be applied without affecting the separation process. In most cases an
aqueous buffer system, suiting the proteins to be purified, will work well.
Protocol:
1. Suspend a Sephadex™ column material or the equivalent in the de-
sired buffer that is used in the chromatography. Equilibrate for at
least two hours under vacuum to degas. Use a magnetic stirrer at
low rpm to mix gently.
2. Pack a column with the suspension. For desalting purposes the
column size should be at least five times the applied sample volume.
Avoid the introduction of air bubbles.
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3. Wash with buffer used in the chromatography step. Ten times the
column size is appropriate.
4. Apply the sample in as small a volume as possible. 1 ml/min is the flow
rate that will work in most cases.
5. Collect fractions of the desired volume and monitor for protein at
260 nm, or take an aliquot of each to perform a Bradford Assay.
4.1.2 Nickel-Chelate Affinity Chromatography
Nickel chelate affinity chromatography is a powerful purification tech-
nique. Proteins and other macromolecules are able to form complexes
with metal ions. The column material consists of an immobilized chelat-
ing agent, able to complex metal ions. Weak associated coordination sites
of the ion then can interact with specific proteins running through the
column. Elution can be performed by
• lowering the pH.
• raising the ionic strength.
• adding a chelating agent such as EDTA, that will compete with the
protein metal complex.
This chromatography system will bind more or less only IgG class im-
munoglobulins, while other proteins will not be retarded. So this method
can be used to extract the IgG fraction of antisera or to purify antibody-
enzyme conjugates. Eluting conditions are rather mild, so activity loss can
be reduced to a minimum. IgGs lacking the Fc part of the antibody do not
interact with Nickel ions and thus can not be purified with this technique.
The following protocol describes how a Ni2+- chelate affinity chromatog-
raphy is done:
1. Pack a column with an appropriate volume of an iminodiacetic acid
support. 1 ml can bind up to 50 mg antibodies, however not more
than 10 − 20 mg should be applied per ml gel.
2. Prepare a 50 mg/ml Ni2+- solution in H2O. Apply 1 ml of this solution
per ml of gel to the column.
3. Wash the column with 5 gel-bed volumes of H2O to remove excess
Ni2+.
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4. Equilibrate with 5 gel-bed volumes of binding buffer: 10 mM sodium
phosphate, 150 mM NaCl, pH 7. The high ionic strength of the buffer
will minimize non specific ionic interactions between the positively
charged support and negatively charged compounds in the sample.
5. Dissolve the sample into binding buffer and apply this solution to
the column. Collect fractions of the desired volume and monitor for
protein at 260 nm, or take an aliquot of each to perform a Bradford
Assay.
6. Wash with 150 mM saline solution until no more protein can be de-
tected. Elute the bound sample using
• 100 mM sodium acetate, 0.5 M NaCl, pH 5
• binding buffer containing 20 mM EDTA
as the elution buffer.
7. Perform a gel filtration to transfer the sample in a suitable storage
buffer.
Figure 4.1: Ni2+- chelated iminodiacetic acid groups can be used to purify antibodies.
The Ni2+- chelate binds to the Fc region so that antibodies are retained, whereas other
enzymes can pass through the column [65].
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4.2 Conjugation And Immobilization
4.2.1 Glutaraldehyde conjugation
Figure 4.2:
Glutaraldehyde
MW 100.11 g/mol
Glutaraldehyde is one of the oldest and at the same
time most popular homobifunctional cross-linker in
use. It was introduced in 1962 by Sabatini et al. as a
fixative for electron microscopy [66]. The reactive alde-
hyde groups are able to form Schiff bases with pri-
mary amines. This reversible bond can be reduced
with NaBH4 to the secondary amine which is stable.
Figure 4.3: Schiff base linkage of primary amines with glutaraldehyde
In aqueous solution glutaraldehyde formsα, β-unsaturated polymers, which
can react with primary amines in a Michael-type reaction, resulting in sec-
ondary amine linkage [67]. Due to its homobifunctional nature the repro-
ducibility of glutaraldehyde conjugates is low. In solution large conjugates
are produced, which will precipitate. But when immobilization on solid
supports is performed these problems are not that severe, because the re-
action steps of activation and conjugation can be separated and so self
polymerization of the bio molecule is not possible. On the carrier surface
Figure 4.4: Self polymerization of glutaraldehyde and Michael-type addition of primary
amines
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the bio molecule can be covalently linked by more than one reactive group.
A so called multi attachment will be achieved. It is unlikely that all Schiff
base linkages will be cleaved at the same time, so that no further reduction
step is needed to gain stable immobilization.
A typical conjugation protocol involving glutaraldehyde:
1. Suspend an amino carrier in a 2.5% solution of glutaraldehyde in
0.05 M phosphate buffer, pH 7. Shake gently for one hour.
2. Wash exhaustively with ice water.
3. Add the amine containing bio component in as small a volume as
possible.
4. React for 2-4 hours at room temperature.
5. Wash with phosphate buffer and store in 0.05 M saline solution at
4°C.
4.2.2 EDC
Figure 4.5: EDC 1-Ethyl-3-[3-dimethylaminopropyl]carbodiimide Hydrochloride
MW 191.7 g/mol
EDC (1-Ethyl-3-[3-dimethylaminopropyl]carbodiimide Hydrochloride) as
introduced in conjugation chemistry by Newman et al., is the carbodiimide
of choice for the use in bio conjugate procedures. Usually biological sub-
stances are water soluble and so is EDC. There is no need to use complicate
buffer systems or organic solvents. Reaction by-products are also solu-
ble in water, hence the product can be purified by a fast and simple gel
filtration.
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Figure 4.6: EDC reaction scheme
EDC reacts with carboxylate
groups to a highly reactive O-
acylisourea. This intermediate
then reacts with primary amines
or other nucleophiles to form an
amide bond. The O-acylisourea
also reacts with sulfhydryl groups,
although these conjugates are not
as stable as those with primary
amines. Oligomerisation will oc-
cur if the molecule to be activated
contains both, a carboxylate and
an amine group. Keep attention
not to use EDC in such systems.
The reaction should be performed
in an aqueous buffer system,
preferably at pH 5. However even
at pH 10 positive results are ob-
tainable. Be careful not to use any buffers, that may contain carboxylates
or primary amines.
An EDC mediated conjugation might be the method of choice for coupling
antibodies to an implant surface, because the resulting amide bond linkage
will not be as immunogenic as other cross linkers are. On the other hand
an antibody molecule possesses several primary amines, so that no specific
site directed linkage is no more possible.
Protocol for EDC conjugation reaction:
1. Dissolve the carboxylate containing reagent in 0.1 M sodium phos-
phate, pH 5. 0.1 M NaCl may be added if desired.
2. Add EDC in at least a 10-fold molar excess of EDC to carboxylate
groups. Activate for one hour at room temperature.
3. Purify the product from excess EDC by gel filtration. If using a solid
support simply wash with buffer.
4. Add the amine containing species to the activated carboxylates and
allow to react for two hours at room temperature.
5. Perform another gel filtration to purify or in the case of solid supports
just wash with buffer.
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4.2.3 EDC + s-NHS
By adding s-NHS to a EDC mediated coupling reaction, the likely hy-
drolysable O-acylisourea intermediate formed by EDC activation is sta-
bilised to a s-NHS ester. The new intermediate is stable long enough in
order to perform two step coupling protocols, hence avoiding self poly-
merisation problems associated with one step protocols.
Figure 4.7: EDC + s-NHS mediated conjugation
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4.2.4 sulfo-SMCC
Figure 4.8: Sulfo-SMCC
MW 436.37 g/mol
Sulfo-SMCC or Sulfosuccinimidyl-4-(N-maleimido-
methyl)-cyclohexane-1-carboxylate is a heterobifunc-
tional cross linker which can be used to conjugate an-
tibodies to a primary amine containing species. The
NHS-ester end of the cross linker reacts with primary
amines, whereas the maleimide group is reactive to-
wards sulfhydryls. The activation and the conjuga-
tion step can be separated, resulting in a very effi-
cient coupling reaction. Furthermore antibodies possess
sulfhydryls only in the hinge region of the molecule,
thus preventing the binding sites to be blocked in the conjugation step.
Figure 4.9: Activation of primary amines followed by coupling with sulfhydryl containing
antibody fragment
At pH 7 the reaction of the maleimide group with sulfhydryls proceeds a
1000 times faster than its reaction with amines. Due to this reason a given
amine containing species can be activated and stored for a quite long time
before the conjugation with sulfhydryls is done. Sulfo-SMCC is widely in
use today for the creation of sophisticated bio conjugates, e.g. antibodies
labeled with nucleotides for cancer therapy [68] or for the incorporation of
antigens in virus like particles [69].
A general conjugation protocol using sulfo-SMCC looks as the following:
1. Dissolve the amine containing species in 0.1 M sodium phosphate,
0.15 M NaCl, pH 7.2 .
2. Add sulfo-SMCC in a 40 to 80 molar excess to this solution. Mix to
dissolve and allow to react for one hour at room temperature.
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3. Purify the activated sample from any excess sulfo-SMCC by gel fil-
tration using Sephadex™ G25, or in the case of solid supports wash
with buffer. At this point the activated sample may be freeze dried
and stored for a few weeks, without losing maleimide activity.
4. Dissolve the sulfhydryl containing species in 0.1 M sodium phos-
phate, 0.15 M NaCl, pH 7.2 . Add the maleimide activated reactant
at the desired molar ratio. React for at least half an hour at 37°C or
one hour at room temperature. The reaction can be done also over
night at 4°C.
5. Wash the immobilized product with buffer or use a gel filtration
column with an appropriate cut off to purify soluble conjugates.
4.2.5 Immobilization of lipoic acid as a reducing agent
Disulfide bridges in bio molecules can be reduced with mercaptoethanol.
A high concentration is needed to drive the reaction to completion due to
the low equilibrium constant. A better choice for a reducing agent is dithio-
threitol. A sterically favoured dithiolane ring is formed in the reduction
reaction. Its still difficult to remove the reduction agent from the sample
solution. At least a gel filtration step is needed, while in the meantime
re-oxidation of the sulfhydryls may occur.
Gorecki et al. introduced a new insoluble reducing support consisting of
immobilized lipoic acid [70]. It can be removed very quickly by centrifuga-
tion to overcome the mentioned problems.
Figure 4.10: Reduction of disulphide with immobilized lipoic acid
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This protocol describes the synthesis of such a support:
1. Prepare 15 ml 0.1 M sodium phosphate, pH 6.3 . Add 5 ml dioxane.
Dissolve 41.2 mg lipoic acid, 43.4 mg sulfo-NHS and 38.4 mg EDC in
this solution and react for 30 minutes at room temperature.
2. Adjust pH to 7.5 with 1 M Na2HPO4 and add 0.5 g aminosilanised
Swarowsky™ glass powder (or other suitable support materials,i.e.
agarose,polyacrylamide . . . ). Incubate over night at room tempera-
ture.
3. Wash the glass powder in a suction funnel, pore size 4, with:
• 5 ml DMF, 3X
• 10 ml EtOH / H2O 1:1, 2X
• 10 ml EtOH, 2X
4. Dry over night at 80°C.
5. Prepare 3 ml 50 mg/ml NaBH4 in H2O. React for 30 minutes at room
temperature.
6. Wash the glass powder in a suction filter, pore size 4, with:
• 10 ml 0.1 M acetic acid, 2X
• 10 ml H2O, 2X
• 10 ml EtOH, 2X
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4.3 Analytics
4.3.1 Bradford Protein Assay
1976 M. Bradford introduced a very sensitive dye-binding assay for protein
detection [71]. It involves the addition of an acidic dye (Coomassie™Brilliant
Blue G-250) to a protein solution and subsequent measurement at 595 nm
with a spectrophotometer. The absorbance maximum for an acidic solution
of the dye shifts from 465 nm to 595 nm when binding to protein occurs.
Beers law can be used for quantification in the linear range of the assay,
which reaches from 2µg/ml and lower up to 120 µg/ml.
Figure 4.11: Coomassie Brilliant Blue
4.3.2 Kaiser Test
The Ninhydrin reaction as developed by Moore and Stein [72] was adapted
for solid phase synthesis by Kaiser et al [73]. Ninhydrin reacts with primary
amines on the surface to form Ruhemann’s Blue (Figure 4.12). Quantifi-
cation of the amines is difficult because Ruhemann’s blue can be found in
solution as well as on the surface. However Sarin et al. claim to overcome
this problem by introducing a ion-exchange wash step, so that Ruhemann’s
Blue will not be able any more to adsorb onto the solid support.
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Figure 4.12: Reaction-scheme of the ninhydrin reaction
The protocol for the Kaiser test is adapted from Sarin et al [74].
1. Dissolve 8 g phenol in 2 ml EtOH.
2. Prepare a 10 mM solution of KCN in 0.2 ml H2O. Fill up to 10 ml with
pyridine.
3. Dissolve 50 mg ninhydrin in 950 mg EtOH.
4. Add 0.5 ml of each solution to a test tube containing the sample.
5. Boil for 5 min in H2O.
The solution turns blue by the presence of primary amines.
4.3.3 Enzyme assay
Enzyme assay is a standard procedure in bio analytics. A broad range of
different tests are well elaborated. In general a substrate development is
monitored over the time. Following Michaelis and Menten in an enzymatic
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reaction a first build enzyme - substrate complex dissociates to form free
enzyme and product.
[E] + [S]
k1
GGGGGBF G
k−1
[ES]
k2
GGGA[E] + [P]
In an initial rate experiment substrate is added in large excess so that
d[S]
dt
≈ 0
and
[E]total = [ES] + [E] ≈ [ES].
The turnover number can be written as
Vcat = k2 ∗ [ES].
Eventually with the known catalytic constant(dissociation constant of the
enzyme substrate complex) k2 of a given enzyme or by a simple compari-
son with a calibration curve using enzyme standards, we can quantify the
amount of active enzyme in a sample. By creating the above mentioned
conditions and measuring substrate development only for a short time,
these experiments are fast and quite free from complications, resulting in
a high reproducibility.
In this thesis calf intestinal alkaline phosphatase is the common enzyme
for initial rate experiments. AP can cleave phosphomonoesters from sub-
strates, i.e. para- Nitro Phenyl Phosphate (p-NPP), which develops a strong
yellow color that can be detected at 405 nm.
Figure 4.13: Alkaline Phosphatase catalysed hydrolysis of p-NPP
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The test is performed in 10 · 10 · 45 mm disposable macro cuvettes.
1. Fill with 4 ml 100 mM TBS, pH = 9.5, containing 100 mM NaCl and
100 mM MgCl2.
2. Add 10µl p- NPP stock solution (50 mg/ml in H2O) and monitor the
extinction over the time at 405 nm in a spectrophotometer.
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Chapter 5
Results and Discussion
The practical work of this thesis consists of the development and evalu-
ation of different techniques for a drug targeting system. My supervisor
Mag. Haifa al Dubai was trying to establish an elaborate type of stent
implant. The implant material should be camouflaged with a biocompati-
ble polymer layer, followed by conjugation of specific binding pockets for
biodegradable nano particles to the layer. At this time the antibody based
binding sites for the polymer beads were not available, so the synthesis
procedure for the drug targeting system was tested using stuff we already
had in our laboratory.
First of all a quantitative method to detect functional groups, which can
be used for coupling on a given surface, is needed. Next different im-
plant materials were coated covalently with Polyethylene glycol (PEG),
followed by quantification of PEG chains. Afterwards I tried to gain some
exercise in antibody chemistry, including several chemical and enzymatic
modification methods as well as with coupling techniques on surfaces.
5.1 Quantification of functional groups on sur-
faces
In general our implant materials are derivatised chemically to contain free
amino groups for coupling steps. The implant materials consist of 316-
L surgical stainless steel and ZrO2 ceramics. Furthermore microscopical
cover glasses are used because of their availability, cheapness and low
background signal in spectrometrical analysis. Amino groups are intro-
duced by silanisation with 3-Aminopropyl-triethoxysilane (see protocol
A.1). The surface needs to contain free hydroxyl groups in order to react
with the silanisation agent. Cover glasses and ZrO2 already have hydroxyl
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groups, whereas 316-L has to be etched to generate some (see protocol A.2).
There exists a widely used analytical method for amino group quantifica-
tion as described in section 4.3.2. Our special problem was the very low
number of amino groups on the surfaces, far below the detection limit
of the Kaiser test. After some discussions we decided to perform an en-
zymatic assay. The free amino groups are activated with a cross linker
followed by conjugation to an enzyme. Now in an initial rate experiment
the enzymatic reaction can be monitored over the time (for more details as
well as theoretical background see section 4.3.3). The slope is proportional
to the concentration of the enzyme, which should be somewhat equal to
the number of amino groups. Eventually the test is not about amino group
quantification but for the quantification of functional groups that are also
available for ligand coupling.
Figure 5.1: AP immobilisation with GA
The quantification tests are
performed in 10 · 10 · 45 mm
disposable macro cuvettes,
containing 4 ml 100 mM TBS,
pH = 9.5, with 100 mM NaCl
and 100 mM MgCl2. The re-
action is started by addition
of 10µl p- NPP stock solu-
tion (50 mg/ml in H2O). The
extinction is monitored over
the time at 405 nm in a spec-
trophotometer. A Pasteur
pipette is used to mix the
cuvette content between the
measure points.
All used protocols as well as
the detailed experimental data can be found in the appendix section. The
amount of immobilised enzyme is calculated using a standard calibration
function (protocol A.6, data B.7 to B.10) giving the following equation:
c [ng/ml] =
k − 0.011
0.247
and m
[
ng
]
= c [ng/ml] · V [ml] ,
whereat c is the concentration of AP, k is the slope in the initial rate exper-
iment, m is the mass of AP and V is the buffer volume in the cuvette (4
ml). The results of the quantification experiments are summarised in the
following table. Different immobilisation setups are organised in blocks
within the table.
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Table 5.1: Quantification of immobilised AP
Sample Description Protocol Data Slope Quantity
AP on glass with GA A.4 B.1 6.93 · 10−4 11 ng
Sample B.1 repeated mes.
after 3 days storage in PBS
A.4 B.6 6.11 · 10−4 10 ng
AP on 0.5 M HCl-etched
316-L with GA
A.5 B.2 5.96 · 10−4 10 ng
AP on 6 M HCl-etched 316-
L with GA
A.5 B.3 3.85 · 10−4 6 ng
AP on 3% HNO3-etched
316-L with GA
A.5 B.4 5.44 · 10−4 9 ng
AP on not etched 316-L
with GA
A.5 B.5 7.74 · 10−5 1 ng
AP on ZrO2 with GA A.12 B.18 2.14 · 10−4 3 ng
AP on 3% HNO3-etched
316-L with EDC pH 5
A.9 B.24 8.6 · 10−4 14 ng
AP on PEGylated (with
p-chloranil) 0.5 M HCl-
etched 316-L with p-
chloranil
A.10 B.11 1.27 · 10−4 2 ng
AP on PEGylated (with
EDC, pH 5) 0.5 M HCl-
etched 316-L with GA
A.7, A.8 B.12 2.44 · 10−4 4 ng
AP on PEGylated (with
EDC, pH 5) 6 M HCl-
etched 316-L with GA
A.7, A.8 B.13 2.38 · 10−4 4 ng
AP on PEGylated (with
EDC, pH 5) 3% HNO3-
etched 316-L with GA
A.7, A.8 B.14 2.38 · 10−4 4 ng
AP on PEGylated (with
EDC, pH 10) 0.5 M HCl-
etched 316-L with GA
A.7, A.8 B.15 2.35 · 10−4 4 ng
AP on PEGylated (with
EDC, pH 10) 6 M HCl-
etched 316-L with GA
A.7, A.8 B.16 2.31 · 10−4 4 ng
Continued on next page
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Table 5.1 – continued from previous page
Sample Description Protocol Data Slope Quantity
AP on PEGylated (with
EDC, pH 10) 3% HNO3-
etched 316-L with GA
A.7, A.8 B.17 2.32 · 10−4 4 ng
Blank sample: AP on not
silanised PEGylated (with
EDC, pH 10) 0.5 M HCl-
etched 316-L with GA
A.7, A.8 B.19 4.16 · 10−6 0 ng
AP on PEGylated (with
EDC, pH 5) 3% HNO3-
etched 316-L with EDC pH
5
A.7, A.9 B.20 3.53 · 10−4 6 ng
AP on PEGylated (with
EDC, pH 10) 3% HNO3-
etched 316-L with EDC pH
10
A.7, A.9 B.21 1.97 · 10−4 3 ng
AP on PEGylated (with
EDC, pH 5) 0.5 M HCl-
etched 316-L with EDC pH
5
A.7, A.9 B.22 5.11 · 10−4 8 ng
AP on PEGylated (with
EDC, pH 10) 0.5 M HCl-
etched 316-L with EDC pH
10
A.7, A.9 B.23 2.51 · 10−4 4 ng
Biotinylated AP (A.15) on
avidin coated cover glass
(A.13)
A.16 B.25 2.51 · 10−3 40 ng
Biotinylated AP (A.15) on
biotinylated cover glass
sample 1 (A.15)
A.17 B.26 2.51 · 10−4 4 ng
Biotinylated AP (A.15) on
biotinylated cover glass
sample 2 (A.15)
A.17 B.27 3.61 · 10−4 6 ng
The first block shows the results of a direct immobilisation of AP on solid
supports. Different etching agents can be compared. Etching with 0.5
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M HCl gives the best results similar to 3% HNO3. With 6 M HCl, the
most concentrated acid, only half of the amount of AP could be detected
as compared to the other etching agents. Not silanised supports do not
give a signal (data not shown). Unetched 316-L stainless steel gives a
signal strength that is one order of magnitude below that one of etched
steel, obviously demonstrating how important the etching step is. The
ZrO2 immobilisate also shows very promising results. The amount of AP
(3 ng) might seem low, but when including the surface of the ZrO2 tab
(≈ 0.3 cm2) in the calculation, it exceeds all other immobilisates (surface
≈ 1.5 cm2). The immobilised amount of AP on glass is equal to that on 316-
L stainless steel. Due to this fact later on all immobilisation experiments
are carried out on glass.
Second block includes a single experiment whereat AP was linked directly
to a silanised 316-L foil using the EDC method (see section 4.2.2). This is
the best support. However because of the time consuming EDC immobili-
sation the experiment was not verified and further investigation is needed.
Third block shows a single support using p-chloranil to conjugate AP on a
PEGylated surface. The quantity of AP is rather low. Moreover p-chloranil
seems not to be an unproblematic chemical when used in living organisms.
No more experiments are performed using p-chloranil as the crosslinker.
Figure 5.2: PEG linked to surface using EDC followed by AP immobilisation with EDC
The following block lists the results of 316-L foils that are camouflaged with
PEG (coupled with EDC). The PEG chains contain a terminal amino group,
which is used to couple AP using GA. After the PEG linking no more dif-
ferences could be observed between the different etching methods. Two
different EDC protocols are used for PEG immobilisation (one working at
pH 5 and one with a pH of 10), giving the same results. When compared
to the direct GA linkage of AP without PEG, only half of the amount could
be immobilised with a PEG chain layer in between the support surface and
the AP.
In the fifth block the results of PEGylated surfaces (using EDC) and sub-
sequent AP coupling with EDC are listed. Now a clear difference between
pH 5 and pH 10 was observed. The pH 5 protocol allows to link approx-
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imately the double quantity of AP to the support as compared to pH 10,
almost reaching the same amounts that have been detected without an
intermediate PEG layer.
Last block shows some avidin biotin experiments. By incubating an avidin
coated cover glass (using GA) with biotinylated AP an amount of 40 ng is
detected, which is one order of magnitude above all other samples. Theo-
retically avidin has four biotin binding sites. That could explain the strong
signal enhancement. The other setup consists of a biotinylated surface
incubated with avidin, followed by incubation with biotinylated AP. The
amount of AP detected falls in the range of the common setups, wherein
AP is directly conjugated to a surface. An explanation for the different
outcomes might be a sterical hindrance of avidin when interacting with
the short biotin chains linked to a surface.
Figure 5.3: Bridged Avidin Biotin immobilisation
Recap
After the disappointing outcomes of the Kaiser Test the new developed
enzymatic method shows very promising results. The detection limit of
this method is far below 1 ng of immobilised enzyme per cm2 of solid
support surface. Results are of high reproducibility. The highest density
of immobilised enzyme is obtained with the EDC conjugation method at
pH 5, followed by the GA method. The microscopical cover glasses are
going to be the solid support of choice for further tests. After etching 316-L
stainless steel, preferably with a 0.5 M solution of HCl, the immobilisate
density reaches the same values as compared to cover glasses.
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5.2 Quantification of antibody based targeting
moieties on surfaces
As already mentioned the specific antibody against the polymer beads was
not available at the time when I started my diploma thesis work. Therefore
some old antibodies from the fridge were used as model antibodies, to gain
some expertise in antibody chemistry, including:
• Monoclonal mouse anti Hemagglutinin antibody (mαHA)1
• Monoclonal biotinylated donkey anti goat antibody (dαg)
• Anti Horseradish Peroxidase antibody from unknown origin (αHRP)
• Polyclonal goat anti mouse antibody HRP conjugate (gαm-HRP)
• Polyclonal rabbit anti mouse antibody HRP conjugate(rαm-HRP)
Before antibody processing the crude antibody solutions are purified in a
Nickel-Chelate affinity chromatography step (see section 4.1.2). All immo-
bilisation experiments are carried out using microscopical cover glasses as
the solid support.
5.2.1 dαg Pretests
In this first antibody experiment the goal was to be able to detect anti-
bodies on a surface. The biotinylated antibody is immobilised using the
GA method (protocol A.21), or the sulfo-SMCC method (A.22). The sulfo-
SMCC procedure (see section 4.2.4) is used for direct coupling of the dαg
antibody on blank surfaces as well as PEGylated surfaces (A.23). For de-
tection an avidin-AP conjugate is created (see A.14). The avidin moiety
should interact with the biotin tag of the immobilised antibody, whereas
the AP can be detected as usual. Unfortunately this setup does not show
a positive outcome.
The next idea was to detect the dαg antibody using a secondary gαm-HRP
conjugate. Usually the secondary antibody binds the primary, but in this
setup the primary antibody (αg) binds the secondary which is from goat
origin. TMB is used as the substrate.
1Provided by Manfred Koranda
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Test setup:
• Place the cover glass in a macro cuvette
• Add 4 ml 0.1 M PBS pH 7
• Add 20µl TMB in EtOH
• Add 40µl H2O2
After 20 seconds the solution begins to turn blue indicating the presence
of HRP. All three different test samples, i.e. dαg on glass with GA, dαg
on glass with sulfo-SMCC and dαg on PEGylated glass with sulfo-SMCC,
developed the blue color. It takes the blank samples more time to develop
the blue colour (after two minutes), but this outcome is considered not to
be good enough for a quantitative test. Some different blocking techniques
have to be evaluated to gain a lower background signal for the blanks.
Figure 5.4: dαg antibody immobilised with GA; The dαg antibody recognises a 2nd
antibody HRP conjugate from goat origin
5.2.2 mαHA Pretests
The experiments from the previous section are repeated using a slightly dif-
ferent setup. A first immobilised antibody, i.e. mαHA, is detected by a 2nd
antibody HRP conjugate (rαm-HRP). Now this is the typical ELISA proce-
dure. The mαHA antibody is linked to the surface using GA or s-SMCC
(protocols A.19 and A.20). After a washing step any bound rαm-HRP is
detected by adding HRP substrate as described in the previous section.
The cover glass surfaces turned blue immediately, already indicating that
the blue dye used for the test is not soluble in water. But for a quantitative
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method in a spectrophotometer a soluble dye is needed in order to gain
a steady signal. The poor solubility of HRP dyes along with the strong
background of the blank samples are considered the biggest issues at this
time.
Figure 5.5: mαHA antibody immobilised with GA; The mαHA antibody is recognised by
a 2nd rαm-HRP in an ELISA like setup
5.2.3 αHRP immobilisation
Until now every setup utilised two antibodies, one immobilised on the
surface and one for detection of the first one. Now a new model is created
in which only one antibody is immobilised. This antibody immediately
recognises a dye developing enzyme that can be used for quantification.
An αHRP antibody is meeting this demands.
The αHRP antibody is linked with GA or s-SMCC (protocols A.25 and
A.26) to the silanised cover glasses. HRP can be used for detection of any
bound αHRP antibody. The detection protocol now includes a block wash
step with an added surfactant and BSA as a blocking agent.
• Wash the cover glass antibody support with 0.1 M sodium phosphate,
0.15 M NaCl, pH 7.2 containing 1 ‰Triton X-100 and 26 mg/ml BSA for
one hour.
• Add 2µl of a 1.5 mg/ml HRP solution.
• Incubate for one hour
• Wash with 0.1 M sodium phosphate, 0.15 M NaCl, pH 7.2 containing
1 ‰Triton X-100 for one hour.
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Figure 5.6: αHRP antibody immobilised with s-SMCC; The αHRP antibody binds HRP
to yield a blue color
• Wash with 0.1 M sodium phosphate, 0.15 M NaCl, pH 7.2 .
• Add 4 ml 0.1 M PBS, pH 7.
• Add 20µl TMB in EtOH
• Add 40µl H2O2
The two αHRP supports (GA and s-SMCC immobilisation) as well as a
positive control, wherein HRP is directly linked to the surface, turned blue
after thirty seconds. Finally the blank sample does not show any color
development after one hour of incubation time.
5.2.4 Evaluation of HRP substrates
After including a blocking step in the quantification protocol the back-
ground of blank samples was no longer a problem. So now we have a
perfect model system beside the fact that the used HRP dye is not water
soluble. When trying to quantify a immobilisate in the spectrophotometer
the signal does not increase steadily. When looking at the cover glasses
it could be seen that the TMB dye adsorbed on the surface falsifying the
measurements.
Hence different HRP substrates are tested, hoping to find a water soluble
one.
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The used substrates include:
• catechol
• resorcinol
• guaiacol (used as a 10% solution in DMSO)
• ascorbic acid
Wave length scans of the different substrates are performed in their re-
duced and oxidised forms. Only catechol and guaiacol show different
spectra in the oxidised form as compared to the reduced one. Catechol
has an absorption maximum at 421 nm, whereas that one of guaiacol can
be found at 477.5 nm. Comparing these maxima with that of a pure HRP
solution (402 nm), guaiacol seems to be the substrate of choice. The peak
of catechol is too near to the HRP peak, thus lowering the detection limit.
Next guaiacol solutions are tested with different concentrations of dis-
solved HRP. The results are promising, showing a steady signal over three
orders of magnitude of HRP concentration.
Table 5.2: Quantification of dissolved HRP with guaiacol
HRP concentration slope
70.6 nM 4.6 ·10−3
7.1 nM 3.5 ·10−4
0.71 nM 3.2 ·10−5
All these tests were performed with dissolved HRP. Now the guaiacol sub-
strate is tested with immobilised HRP and once again the oxidised guaiacol
adsorbed on the cover glass. In the end no suitable HRP substrate, which
is soluble in water and does not adsorb on glass surfaces, could be found.
5.2.5 A HRP-AP chimaera
Having in mind the idea of Ehrlich, that a haptophore does not necessarily
have a therapeutic effect and should therefore be combined with a drug
molecule similar to an arrow poison, another setup is developed. The
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haptophore moiety consists of the HRP enzyme, that can attach to the
surface bound αHRP antibody. But as seen before the analytical (instead
of the therapeutic) effect of HRP is quite frustrating. So why not combine
it with an enzyme that has great potential in analytics, for example AP,
which has already prevailed in previous tests.
HRP has some sugar residues that can be oxidised to aldehydes using
NaIO4. These aldehyde groups can react with amino residues of AP giving
a Schiff base linkage, which is reduced to the secondary amine using NaBH4
(for further details see protocols A.27 and A.29).
The resulting HRP-AP chimaera can be quantified easily using the same
setup as described in section 5.1.
5.2.6 Quantification of GA immobilised antibodies
Now the antibody immobilisates are quantified using the new AP-HRP
conjugate. All immobilisates are prepared as described in protocol A.25,
wherein the αHRP antibodies are coupled to the amino silanised cover
glasses with the GA method (section 4.2.1).
Figure 5.7: αHRP antibody immobilised with GA; TheαHRP antibody binds the HRP-AP
conjugate to yield a yellow color
The block-wash step from section 5.2.3 is adapted to the AP-HRP conjugate:
• Wash the cover glass antibody support with 0.1 M sodium phosphate,
0.15 M NaCl, pH 7.2 containing 1 ‰Triton X-100 and 26 mg/ml BSA for
one hour.
• Add 2µl of a 1.5 mg/ml AP-HRP solution.
• Incubate for one hour
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• Wash with 0.1 M sodium phosphate, 0.15 M NaCl, pH 7.2 containing
1 ‰Triton X-100 for thirty minutes.
• Wash with 100 mM TBS, pH = 9.5, with 100 mM NaCl and 100 mM
MgCl2 for 10 minutes.
• Add 4 ml 100 mM TBS, pH = 9.5, with 100 mM NaCl and 100 mM
MgCl2 along with the support in a 10 · 10 · 45 mm disposable macro
cuvette
• Add 10µl p- NPP stock solution (50 mg/ml in H2O) to start the reaction.
• Monitor extinction over time at 405 nm in a spectrophotometer, mix-
ing the cuvette content with a pasteur pipette between measure
points.
The following table lists the results from these first quantitative tests. The
calculated amounts are not that accurate, because the activity of the new
HRP-AP might not be comparable to that one of the pure AP. However the
results should give the range of immobilised antibodies to have somewhat
an idea of how much is immobilisable.
Table 5.3: Quantification of GA immobilised αHRP antibodies (part A)
Sample Description Data Slope Quantity
αHRP on cover glass with GA,
incubated with AP; blank 1
B.28 9.41 · 10−6 ≈ 0 ng
BSA on cover glass with GA, in-
cubated with AP-HRP; blank 2
B.29 −2.98 ·10−6 ≈ 0 ng
αHRP on cover glass with GA,
incubated with AP-HRP; sample
1
B.30 9.33 · 10−5 ≈ 1.3 ng
αHRP on cover glass with GA,
incubated with AP-HRP; sample
2
B.31 1.43 · 10−4 ≈ 2.1 ng
αHRP on cover glass with GA,
incubated with AP-HRP; sample
3
B.32 1.65 · 10−4 ≈ 2.5 ng
αHRP on cover glass with GA,
incubated with AP-HRP; sample
4
B.33 1.73 · 10−4 ≈ 2.6 ng
Continued on next page
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Table 5.3 – continued from previous page
Sample Description Data Slope Quantity
sample 1; repeated measure-
ment2
B.34 6.11 · 10−4 ≈ 0.8 ng
sample 2; repeated measure-
ment
B.35 7.38 · 10−5 ≈ 1 ng
sample 3; repeated measure-
ment
B.36 8.07 · 10−5 ≈ 1.1 ng
sample 4; repeated measure-
ment
B.37 5.41 · 10−5 ≈ 0.7 ng
The amount of immobilised antibodies lies somewhere in the range of 2
ng per cover glass. Blank 1 shows no cross reactivity of pure AP with the
immobilised αHRP antibody. Blank 2 shows that now unspecific adsorp-
tion on the cover glass takes place. After ten days of storage at 4°C only
half of the initially coupled antibodies are detected. The reasons might be
the labile Schiff Base linkage of the antibodies, as well as activity loss of
AP-HRP when stored in a pH=7.2 buffer.
2After ten days storage in PBS pH=7.2 at 4°C
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2nd round of quantification of GA immobilised antibodies
Another four samples are prepared as described above. Results are listed
in the following table:
Table 5.4: Quantification of GA immobilised αHRP antibodies (part B)
Sample Description Data Slope Quantity
αHRP on cover glass with GA,
incubated with AP-HRP; sample
1
B.38 1.52 · 10−4 ≈ 2.3 ng
αHRP on cover glass with GA,
incubated with AP-HRP; sample
2
B.39 9.07 · 10−5 ≈ 1.3 ng
αHRP on cover glass with GA,
incubated with AP-HRP; sample
3
B.40 2.58 · 10−4 ≈ 4 ng
αHRP on cover glass with GA,
incubated with AP-HRP; sample
4
B.41 2.28 · 10−4 ≈ 3.5 ng
αHRP on cover glass with GA,
incubated with AP; blank 1
B.42 1.77 · 10−5 ≈ 0.1 ng
αHRP on cover glass with GA,
incubated with AP; blank 2
B.43 1.68 · 10−5 ≈ 0.1 ng
sample 1; repeated measure-
ment3
B.44 9.55 · 10−5 ≈ 1.4 ng
sample 2; repeated measure-
ment4
-xxx- -xxx- -xxx-
sample 3; repeated measure-
ment
B.45 9.21 · 10−5 ≈ 1.3 ng
sample 4; repeated measure-
ment
B.46 1.95 · 10−4 ≈ 3 ng
In this experiment series the amount of immobilised antibody varied from
1.3 to 4 ng. Blanks showed no cross reactivity with pure AP. Some problems
3After two days storage in PBS pH=7.2 at 4°C
4Sample 2 was destroyed falling on the floor
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arose during sample storage. Sample 2 was completely destroyed, whereas
sample 1 and 3 broke in pieces. The results from the repeated measurement
are therefore not comparable. However it is quite apparent that storage
of the GA conjugates results in severe activity loss even in a short storage
period of two days.
Looking at the whole picture of all GA immobilisates, this technique results
in low stability conjugates with a low reproducibility. Hence the method
will not meet the demands required to design auspicious medical devices.
5.2.7 Quantification of s-SMCC immobilised antibodies
Antibody immobilisates are quantified using the new AP-HRP conjugate.
All immobilisates are prepared as described in protocol A.26, wherein the
αHRP antibody fragments are coupled to the amino silanised cover glasses
with the s-SMCC method (section 4.2.4). The test is performed as described
in the previous section.
Figure 5.8: αHRP antibody fragment immobilised with s-SMCC; The αHRP antibody
binds the HRP-AP conjugate to yield a yellow color
The following table summarises the results of s-SMCC conjugates:
Table 5.5: Quantification of s-SMCC immobilised αHRP antibody fragments
Sample Description Data Slope Quantity
αHRP fragment on cover glass
with s-SMCC, incubated with
AP-HRP; sample 1
B.47 3.05 · 10−4 ≈ 4.8 ng
Continued on next page
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Table 5.5 – continued from previous page
Sample Description Data Slope Quantity
αHRP fragment on cover glass
with s-SMCC, incubated with
AP-HRP; sample 2
B.48 2.66 · 10−4 ≈ 4.1 ng
αHRP fragment on cover glass
with s-SMCC, incubated with
AP-HRP; sample 3
B.49 3.76 · 10−5 ≈ 0.4 ng
αHRP fragment on cover glass
with s-SMCC, incubated with
AP-HRP; sample 4
B.50 2.46 · 10−4 ≈ 3.8 ng
αHRP fragment on cover glass
with s-SMCC, incubated with
AP-HRP; sample 5
B.51 1.54 · 10−4 ≈ 2.3 ng
αHRP fragment on cover glass
with s-SMCC, incubated with
AP-HRP; sample 6
B.52 1.65 · 10−4 ≈ 2.5 ng
αHRP fragment on cover glass
with s-SMCC, incubated with
AP; blank
B.53 −2.94 ·10−6 ≈ 0 ng
sample 1; repeated measure-
ment 5
B.54 9.37 · 10−4 ≈ 1.3 ng
sample 2; repeated measure-
ment
B.55 1.27 · 10−4 ≈ 1.9 ng
sample 3; repeated measure-
ment
B.56 1.88 · 10−5 ≈ 0.1 ng
sample 4; repeated measure-
ment
B.57 1.18 · 10−4 ≈ 1.7 ng
sample 5; repeated measure-
ment
B.58 1.27 · 10−4 ≈ 1.9 ng
sample 6; repeated measure-
ment
B.59 1.28 · 10−4 ≈ 1.9 ng
sample 1; repeated measure-
ment 6
B.60 1.24 · 10−7 ≈ 0 ng
Continued on next page
5After four days storage in PBS pH=7.2 at 4°C
6After 23 days storage in PBS pH=7.2 at 4°C
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Table 5.5 – continued from previous page
Sample Description Data Slope Quantity
sample 2; repeated measure-
ment
B.61 3.85 · 10−5 ≈ 0.5 ng
sample 3; repeated measure-
ment
B.62 −5.79 ·10−5 ≈ 0 ng
sample 4; repeated measure-
ment
B.63 2.64 · 10−5 ≈ 0.2 ng
sample 5; repeated measure-
ment
B.64 5.24 · 10−5 ≈ 0.7 ng
sample 6; repeated measure-
ment
B.65 4.09 · 10−5 ≈ 0.5 ng
For a better view on the degradation of these samples have a look at the
following table.
Table 5.6: Degradation of s-SMCC supports
Sample After 1
Day (ng)
After 4
Days (ng)
After 23
days (ng)
1 4.8 1.3 0
2 4.1 1.9 0.5
3 0.4 0.1 0
4 3.8 1.7 0.2
5 2.3 1.9 0.7
6 2.5 1.9 0.5
The amount of coupled antibody seems quite high in the first round of
testing. Sample 3 is a failure and is not going to be included in the discus-
sion. After a initial bleeding out phase all samples show the same amount
of immobilised antibody after 4 days storage. This means that then no
more unspecifically or labile bound antibody is present on the support.
The result is very accurate with amounts varying from 1.7 to 1.9 ng in four
samples.
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The long term stability (23 days) of this method is not bad either. Stor-
age conditions were not ideal and in the end infections could be seen in the
storage flasks. Nevertheless a small rest of activity could be detected. The
reason for the decrease is probably not the lability of the antibody support
but that of the AP itself.
In general the s-SMCC coupling is the method of choice comparing it to
the GA technique due to:
• Higher density of immobilised binding sites
• Better stability of the support
• Site directed coupling of the targeting moieties
For further long term stability tests a variation of the method is needed, in
which the analyte (in our case AP) can be reloaded in every round of testing.
5.3 Gimmicks
After having figured out the enormous potential of heterogeneous reac-
tions, some solid supports useful for different reaction steps were synthe-
sised.
Normally a time consuming chromatography step is needed when process-
ing proteins (antibodies) chemically. Within chromatography unreacted
reagents as well as by products and so on are removed. This is necessary
because sometimes these reagents will interfere in following reaction steps.
For example: When coupling antibodies through the sulfhydryl residues
in the hinge region, they are reduced with a sulfhydryl containing agent.
This reactant is added in large excess to drive the reduction to completion.
Then in a later coupling step, targeting the sulfhydryls, the crosslinker
with affinity to the latter will never find a reduced antibody in the huge
sulfhydryl pool of the reducing agent.
To avoid the chromatography step an immobilisation of lipoic acid on glass
powder was performed (for details see protocol A.33). The powder is sim-
ply added to the antibodies and removed by filtration or centrifugation,
with the antibodies ready to use.
The lipoic acid - glass powder support shows a specific activity of 3.17 mmol/g
when compared to pure lipoic acid in an Ellmann’s Assay7. This means that
7The disulfide bond in Ellmann’s reagent, 5,5’-dithio-bis-(2-nitrobenzoic acid), is
cleaved by present sulfhydryls and the products are detected photometrically
54
when one would need an amount of 3.17 mmol of lipoic acid for reduction,
1 g of glass powder support has to be used. Because of the heterogeneous
nature of this reducing device, the reduction step is no more an equilibrium
reaction, thus much less reactant is needed as compared to soluble ones,
e.g. β-mercaptoethanol.
Another support consists of immobilised pepsin on alumina (protocol A.32.
This is useful for antibody cleavage8. The support was tested in a digestion
assay using Coomassie™Brilliant Blue G-250 stained BSA. The absorption
of the stained BSA decreases when digested by pepsin. After comparing
the results to pure pepsin standards an amount of 0.5µg per mg of alumina
was found.
Given that the drug “trucks” in our system consist of PLGA nano beads,
some detection tools were synthesised including:
• Immobilised PLGA on glass powder using the s-NHS + EDC tech-
nique (protocol A.35), as a affinity chromatography support for pu-
rification of potential PLGA antibodies.
• An AP-PLGA conjugate (protocol A.36) as a detection tool for PLGA
antibodies, somewhat similar to 2nd antibody-enzyme conjugates
used in ELISA staining, with a PLGA chain as targeting moiety.
At this time I was at the end of my practical work. Therefore no charac-
terisation experiments were performed with these last two supports. But
like the rest of the gimmicks they might be useful for my supervisor and
potential successors.
8Pepsin digestion leads to one F(ab’)2 antibody fragment.
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Chapter 6
Conclusion and Future
Perspectives
The within this thesis developed detection method, using AP, has proven
to be very sensitive with a detection limit below 1 ng. On average an
amount of approximately 1 ng AP per cm2 of support surface was found.
Considering a typical drug dosage of 0.1 mg/kg a support surface of≈ 100 cm2
is needed in order for the drug to have an effect in a clearly localised area
of 10 ml in volume. This might be a hindrance to the potential applicability
of such a system. However these calculations are a rough estimation and
have to be evaluated within in vivo tests anyway.
For future perspectives I recommend to include the methods presented
in the introduction chapter in the production process of a drug targeting
system. In my opinion the most powerful type of system consists of:
• An in vivo scanning for potential targets using scFv, aptamer or OP
libraries
• Isolation of the promising candidates
• Conjugation to drug loaded degradable polymer beads
Maybe one day it is possible to perform a biopsy of an affected area, use
the specimen to scan for targeting ligands and couple positives to drugs.
That would be a highly individual therapy, wherein every patient has his
own personal drug targeting system.
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Appendix A
Protocols
This section gives a short description of the experimental work in chrono-
logical order. Consider the fact that most experiments where pretests and
the used conditions may be far from optimum. The results of possible
product characterisations are listed in section B.
A.1 Silanisation of surfaces
The only important aspect for a successful reaction is that the sample
possesses active hydroxy groups, which can react with the silanisation
agent. Cover glasses and ZrO2 samples used in this work already contain
those groups, whereas steel samples have to be etched to introduce them.
The following method is used in all of the silanisation steps in this thesis:
Activate the sample for one hour in a 5% solution of aminosilane in 95%
EtOH at room temperature. Wash with EtOH and dry over night at 110°C.
A.2 Etching of 316-L stainless steel
A mild etching procedure is needed to introduce active hydroxy groups
for further silanisation. Cut a 316-L foil in small pieces of approximately
1 cm. 0.5 M HCl, 6 M HCl and 3% HNO3 are the etching agents of choice.
Etch for 15 min at room temperature. A fast spot test using a filter paper
treated with 5% NaSCN can be useful to detect iron ions in the acids, thus
indicating successful etching.
Store in H2O for at least two days to ensure hydroxy group formation.
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A.3 Kaiser test for amino group determination
Dissolve 8 g phenol in 2 ml EtOH. Prepare a 10 mM solution of KCN in
0.2 ml H2O. Fill up to 10 ml with pyridine. Dissolve 50 mg ninhydrin in
950 mg EtOH. Add 0.5 ml of each solution to a test tube containing the
sample. Boil for 5 min in H2O.
A.4 Alkaline phosphatase on glass with glutar-
aldehyde
Fill an eprouvette containing aminosilanised cover glasses with 3 ml of a
2.5% glutaraldehyde solution in 0.05 M PBS, pH 7. Shake gently for one
hour. Wash with large amounts of ice water. Dissolve 40µl of alkaline
phosphatase solution in 300µl of 0.05 M PBS pH 7. Add 100µl of this
solution to each of the cover glasses placed on a microscope slide. Incubate
over night in a wet box at room temperature. Wash them exhaustively with
PBS. Store in 0.05 M saline solution at 4°C.
A.5 Alkaline phosphatase on 316-L foil with glu-
taraldehyde
Prepare a 2.5% glutaraldehyde solution in 0.05 M PBS, pH 7. Add 4 ml to
the aminosilanised 316-L foil in a test tube. Shake for one hour. Wash with
ice/H2O. Dilute alkaline phosphatase to a final concentration of 22 µg/ml in
0.05 M PBS, pH 7. Add 200µl of this solution to each of the 316-L foils.
Incubate over night in a wet box at room temperature. Wash with PBS and
store in 0.05 M saline solution at 4°C.
A.6 Calibration function alkaline phosphatase
Prepare a stock solution of alkaline phosphatase at a concentration of
4.5 µg/ml in 0.1 M TBS containing 0.15 M NaCl and 5 mM MgCl2, pH 9.5.
Add different aliquots from 0.5µl to 4µl in a disposal cuvette and fill up to
4 ml with TBS. Measure absorption in a spectrophotometer against a blank
at 405 nm.
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A.7 PEGylation of 316-L using EDC
A terminal carboxylate group is needed to perform EDC mediated cou-
pling. Dissolve 1 g succinic anhydride in 75 ml 0.5 M phosphate buffer,
pH 6.1. Add 25 ml of this solution to the aminosilanised 316-L foils in a
test tube. Shake over night at room temperature. The amino groups are
transformed into carboxylates, which can be activated with EDC. Two dif-
ferent buffer systems are tested. Prepare 30 ml of 0.1 M citrate buffer (pH
5) and carbonate buffer (pH 10). Add 50 mg EDC and 0.4 g bis-AminoPEG
to each. Incubate each 316-L foil in 10 ml of the different buffers over night
at room temperature. Wash with PBS.
A.8 AP on PEGylated 316-L with glutaraldehyde
After the PEG coupling (Protocol A.7) AP can be attached to the terminal
amino group of the PEG chains. Each sample is activated for one hour
in 1.5 ml 2.5% glutaraldehyde solution in 0.05 M PBS, pH 7. Wash with
ice/H2O. Add 0.2 ml PBS containing 11 µg/ml alkaline phosphatase to each
sample. Incubate over night at room temperature. Wash with PBS and
store in 0.05 M saline solution at 4°C.
A.9 AP on PEGylated 316-L with EDC
The PEGylated 316-L prepared in experiment A.7 are activated once again
with 2.5 ml phosphate buffer (0.5 M, pH 6.1) containing 0.22 g succinic
anhydride over night at room temperature to transform the terminal amino
group of the PEG chain into a carboxylate. Wash with PBS. Split the
samples. Activate half of them in 0.1 M citrate buffer (pH 5) and the other
ones in 0.1 M carbonate buffer (pH 10). Add 1 ml of the chosen buffer with
5 mg EDC to each sample. Incubate for 90 min. Prepare a solution of AP
in citrate/ carbonate buffer (see protocol A.7) at a concentration of 11 µg/ml.
Drop 0.4 ml to each sample and react over night at room temperature.
Wash with PBS and store in 0.05 M saline solution at 4°C.
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A.10 PEGylation and coupling of AP on 316-L
with p-chloranil
Prepare a 1% solution of p-chloranil in toluene. Add the aminosilanised
316-L foils and react for 30 min at room temperature. Wash with toluene,
acetone and H2O. Dissolve 0.1 g bis-AminoPEG in 5 ml H2O. Incubate the
activated samples for 90 min in this solution. Wash with H2O.
The immobilized PEG chains are activated once again with 1% p-chloranil
in toluene for 30 min at room temperature. Wash with toluene, acetone
and H2O. Prepare a solution of AP in 0.05 M PBS at a concentration of
7 µg/ml. Add 0.2 ml to each sample and allow to react over night at room
temperature. Wash with PBS and store in 0.05 M saline solution at 4°C.
A.11 PEGylation of glass using glutaraldehyde
Activate five cover glasses in 16 ml of a 2.5% glutaraldehyde solution in
0.05 M PBS pH 7 for one hour at room temperature. Wash with ice/H2O.
Incubate in 16 ml 0.05 M PBS containing 0.5 g bis-AminoPEG over night at
room temperature. Wash with PBS and store in 0.05 M saline solution at
4°C.
A.12 AP on ZrO2 with glutaraldehyde
A silanised ZrO2 tab is activated for 1 hour with a 2.5% glutaraldehyde
solution in 0.05 M PBS, pH 7. Wash with ice/H2O. Add AP in 0.05 M PBS
at a concentration of 11µl to the sample. Allow to react over night at room
temperature. Store in 0.05 M saline solution at 4°C.
A.13 Immobilization of proteins on glass with
glutaraldehyde
Activate aminosilanised cover glasses in a 2.5% glutaraldehyde solution
in 0.05 M PBS at pH 7 for one hour at room temperature. Prepare the
following protein solutions:
• 0.5µl biotinylated donkey anti goat antibody in 0.2 ml 0.05 M PBS,
pH 7.
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• 0.1 mg HSA in 0.2 ml 0.05 M PBS, pH 7.
• 0.1 mg avidin in 0.2 ml 0.05 M PBS, pH 7.
• 0.1 mg streptavidin in 0.2 ml 0.05 M PBS, pH 7.
Wash the cover glasses with ice/H2O and incubate with the different solu-
tions over night at room temperature. Wash with PBS and store in 0.05 M
saline solution at 4°C.
A.14 AP-Avidin conjugate
Prepare 0.25 ml of a solution containing 1 mg/ml avidin and 4 mg/ml AP in
0.2 M PBS with 0.15 M NaCl, pH 7.4. Add 2.5µl of 25% glutaraldehyde
in H2O to the solution, mix and react for one hour at room temperature.
To quench any excess aldehyde groups add 10µl of 0.2 M lysine in 0.5 M
carbonate buffer, pH 9.5. Block for two hours at room temperature.
The conjugate is purified by gel filtration. Fill a 3 ml disposal column
with Sephadex™ G-25 in PBS to a final bed volume of approximately 2 ml.
Chromatography is performed with a peristaltic pump at a flow rate of
1 ml/min using PBS at pH 7 as elution buffer. Dextran blue elutes at 2.4 ml,
whereas dnp-glycine appears at 3.5 ml. Wash the column with 20 ml elution
buffer before applying the sample solution. Collect 0.5 ml fractions. The
fractions are tested for AP activity. Take a 10µl aliquot of each fraction and
dilute it to 100µl with 100 mM TBS, pH = 9.5, containing 100 mM NaCl
and 100 mM MgCl2. Add 1µl of a 5 mg/ml p- NPP stock solution. Fractions
containing AP-avidin conjugate will turn yellow immediately. Pool the
active fractions and store at 4°C.
A.15 Biotinylation of glass and AP
Suspend 100 mg biotin in 0.5 ml H2O. Add 1 M NaOH until the suspension
turns clear. The total volume increases to 3 ml. Dissolve 80 mg EDC in
0.5 ml in H2O. Mix the two solutions and shake for two hours at room
temperature.
In the coupling step biotin is reacted in a ten fold excess. Take 0.55 ml of
AP stock solution (9 mg/ml, 3.51 ∗ 10−5 mol) and add 3 ml of the activated
biotin (1.17 ∗10−4 mol/ml, 3.51 ∗10−4 mol). Split the remaining 0.5 ml biotin on
two aminosilanised cover glasses. Incubate both approaches over night at
room temperature.
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Wash the cover glasses with PBS and store in 0.05 M saline solution at 4°C.
The AP conjugate is purified by gel filtration with the column prepared in
experiment A.14. Use PBS pH 7 as elution buffer at a flow rate of 1 ml/min.
Apply 300µl aliquots and collect 300µl fractions. Monitor for AP activity
(see experiment A.14). Pool the fractions showing AP activity and store at
4°C.
A.16 Biotinylated AP on avidin coated glass
Add 100µl biotinylated AP (see experiment A.15) to a cover glass with
immobilized avidin (experiment A.13). Wash twice with 0.05 M PBS and
then with 100 mM TBS, pH = 9.5, containing 100 mM NaCl and 100 mM
MgCl2.
A.17 Biotinylated AP on biotinylated glass
Incubate the biotinylated cover glasses with 100µl 0.5 mg/ml avidin in 0.05 M
PBS, pH 7. Wash with PBS. Dilute 100µl biotinylated AP to 200µl with PBS.
Add 100µl to each cover glass. Incubate for 30 min at room temperature.
Wash with PBS and then with 100 mM TBS, pH = 9.5, containing 100 mM
NaCl and 100 mM MgCl2.
A.18 Ni2+ chelate affinity chromatography of
mαHA antibody
Fill a 3 ml disposal column with iminodiacetic acid beads (Pierce) to a final
bed volume of 1 ml. Attach a peristaltic pump. Wash with 10 ml H2O at
1 ml/min. Load the iminodiacetic acid support with 0.5 ml of 0.5 M NiSO4·6 H2O in H2O at a flow rate of 0.5 ml/min. Wash with 15 ml of 0.01 M PBS
containing 0.15 M NaCl at pH 7 (binding buffer). Apply 2 ml mαHA serum
at a flow rate of 0.3 ml/min. Wash with 20 ml binding buffer at 1 ml/min. Elute
with 0.1 M NaOAc containing 0.5 M NaCl at pH 5. Collect 250µl fractions.
Take a 5µl aliquot of each and add 10µl of Bio-Rad™ protein assay diluted
1:4 in H2O. Fractions containing antibody will develop a strong blue color.
Neutralize by adding 2.5µl 1 M NaOH to each fraction and store at 4°C.
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A.19 mαHA on glass with glutaraldehyde
Activate the aminosilanised cover glasses in a 2.5% glutaraldehyde solu-
tion in 0.05 M phosphate buffer with 0.15 M NaCl, pH 7. for one hour at
room temperature. Wash with ice/H2O. Add 100µl purified antibody (see
experiment A.18 to each cover glass and incubate for two hours at room
temperature. Wash three times 15 min with PBS.
A secondary antibody is used to check for successful coupling. Add 2µl
2nd rαm-HRP (rabbit anti mouse - HRP conjugate) in 100µl PBS to each
cover slip. Incubate for 30 min at room temperature. Wash three times
15 min with PBS. Incubate the cover glasses in 0.05 M PBS containing 40µl
H2O2 and 4µl 1 mM TMB in EtOH. HRP can oxidize TMB to yield a blue
dye.
A.20 mαHA on glass with sulfo-SMCC
Dilute 100µl Ni2+-chelate purified mαHA antibody (from experiment A.18)
in 100µl sodium phosphate containing 0.15 M NaCl, 10 mM EDTA, pH 7.2.
Add 1.5 mg 2-mercaptoethylamine and mix to dissolve. React for 90 min
at 37°C.
The aminosilanised cover glasses are activated in 0.1 M phosphate buffer
containing 0.15 M NaCl, 1 mg/ml sulfo-SMCC, pH 7.2. Allow to react for
30 min at room temperature. Wash with PBS and store wet until the anti-
bodies are ready for coupling.
The reduced mαHA antibody is purified from excess mercaptoethylamine
by gel filtration over Sephadex™ G25 using the column from exp. A.14.
Elute with 0.1 M PBS containing 0.15 M NaCl, 0.01 M EDTA, pH 7.2 at a
flow rate of 1 ml/min. Collect 250µl fractions and monitor for the antibody
using Bio-Rad™ protein assay as described in experiment A.18. For a suc-
cessful coupling step it is extremely important that mercaptoethylamine
is removed quantitatively. Pool the antibody containing fractions, dilute
to the desired volume with PBS and add the solution immediately to the
previously activated cover slips. The reduced sulfhydryl groups of the
antibody fragments can be oxidized easily, thus longer storage is not rec-
ommended. Incubate over night at 4°C. Wash with PBS and store in 0.05 M
saline solution at 4°C.
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A.21 dαg on glass with glutaraldehyde
The aminosilanised cover glasses are activated in a 2.5 % glutaraldehyde
solution in 0.1 M sodium phosphate with 0.15 M NaCl, pH 7.2, for one hour
at room temperature. Wash with ice/H2O. Dilute the dαg antibody 1:10
in 0.1 M sodium phosphate, 0.15 M NaCl, pH 7.2 and add a 100µl aliquot
to each activated cover glass. Allow to react over night at 4°C. Wash with
PBS and store in 0.05 M saline solution at 4°C.
A.22 dαg on glass with sulfo-SMCC
Dilute 30µl dαg antibody to 130µl with PBS containing 0.15 M NaCl,
10 mM EDTA, pH 7.2. Add 1 mg 2-mercaptoethylamine and mix to dis-
solve. React for 90 min at 37°C.
The aminosilanised cover glasses are activated in 0.1 M phosphate buffer
containing 0.15 M NaCl, 1 mg/ml sulfo-SMCC, pH 7.2. Allow to react for
30 min at room temperature. Wash with PBS and store wet until the anti-
bodies are ready for coupling.
The reduced dαg antibody is purified from excess mercaptoethylamine
by gel filtration over Sephadex™ G25 using the column from exp. A.14.
Elute with 0.1 M PBS containing 0.15 M NaCl, 0.01 M EDTA, pH 7.2 at a
flow rate of 1 ml/min. Collect 250µl fractions and monitor for the antibody
using Bio-Rad™ protein assay as described in experiment A.18. Pool the
antibody containing fractions, dilute to the desired volume with PBS and
add the solution immediately to the previously activated cover slips. In-
cubate over night at 4°C. Wash with PBS and store in 0.05 M saline solution
at 4°C.
A.23 dαg on PEGylated glass with sulfo-SMCC
Dilute 5µl dαg antibody to 55µl with PBS containing 0.15 M NaCl, 10 mM
EDTA, pH 7.2. Add 1 mg 2-mercaptoethylamine and mix to dissolve. Re-
act for 90 min at 37°C.
The PEGylated cover glasses (from experiment A.11) are activated in 0.1 M
phosphate buffer containing 0.15 M NaCl, 1 mg/ml sulfo-SMCC, pH 7.2. In-
cubation should be performed in a larger volume than 200µl, due to the
extreme hydrophobicity of the PEGylated glass. Allow to react for 30 min
at room temperature. Wash with PBS and store wet until the antibodies
are ready for coupling.
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The reduced dαg antibody is purified from excess mercaptoethylamine
by gel filtration over Sephadex™ G25 using the column from exp. A.14.
Elute with 0.1 M PBS containing 0.15 M NaCl, 0.01 M EDTA, pH 7.2 at a
flow rate of 1 ml/min. Collect 250µl fractions and monitor for the antibody
using Bio-Rad™ protein assay as described in experiment A.18. Pool the
antibody containing fractions, dilute to the desired volume with PBS and
add the solution immediately to the previously activated cover slips. In-
cubate over night at 4°C. Wash with PBS and store in 0.05 M saline solution
at 4°C.
A.24 HRP on glass with glutaraldehyde
An aminosilanised cover glass is activated in a 2.5 % glutaraldehyde solu-
tion, containing 0.1 M sodium phosphate with 0.15 M NaCl, pH 7.2, for one
hour at room temperature. Wash with ice/H2O. Dilute 1µl of a 1 mg/ml HRP
solution to a final volume of 200µl with 0.1 M sodium phosphate, 0.15 M
NaCl, pH 7.2 and add this mixture to the activated cover glass. Allow to
react over night at 4°C. Wash with PBS and store in 0.05 M saline solution
at 4°C.
A.25 αHRP on glass with glutaraldehyde
An aminosilanised cover glass is activated in a 2.5 % glutaraldehyde solu-
tion, containing 0.1 M sodium phosphate with 0.15 M NaCl, pH 7.2, for one
hour at room temperature. Wash with ice/H2O. Dilute 1µl of the αHRP
solution to a final volume of 200µl with 0.1 M sodium phosphate, 0.15 M
NaCl, pH 7.2 and add this mixture to the activated cover glass. Allow to
react over night at 4°C. Wash with PBS and store in 0.05 M saline solution
at 4°C.
A.26 αHRP on glass with sulfo-SMCC
Dilute 1µl αHRP antibody to 50µl with PBS containing 0.15 M NaCl,
10 mM EDTA, pH 7.2. Add 1 mg 2-mercaptoethylamine and mix to dis-
solve. React for 90 min at 37°C.
The aminosilanised cover glasses are activated in 0.1 M phosphate buffer
containing 0.15 M NaCl, 1 mg/ml sulfo-SMCC, pH 7.2. Allow to react for
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30 min at room temperature. Wash with PBS and store wet until the anti-
bodies are ready for coupling.
The reduced αHRP antibody is purified from excess mercaptoethylamine
by gel filtration over Sephadex™ G25 using the column from exp. A.14.
Elute with 0.1 M PBS containing 0.15 M NaCl, 0.01 M EDTA, pH 7.2 at a
flow rate of 1 ml/min. Collect 250µl fractions and monitor for the antibody
using Bio-Rad™ protein assay as described in experiment A.18. Pool the
antibody containing fractions, dilute to the desired volume with PBS and
add the solution immediately to the previously activated cover slips. In-
cubate over night at 4°C. Wash with PBS and store in 0.05 M saline solution
at 4°C.
A.27 NaIO4 activation of HRP
Dissolve 2 mg HRP in 200µl 0.01 M sodium phosphate, containing 8.8 mM
NaIO4. Protect from light and allow to react for one hour at room temper-
ature.
Purify the activated HRP from excess NaIO4 by gel filtration over Sephadex™
G25 using the column from exp. A.14. The HRP containing fractions are
identified by the characteristic brown green color of activated HRP. Pool
the fractions containing the enzyme and store at 4°C.
A.28 Biocytin conjugated with NaIO4 activated
HRP
Dissolve 0.5 mg biocytin in 0.5 ml eluate from experiment A.27 containing
the NaIO4 activated HRP. Adjust the pH to 9 with 20µl of 1 M sodium
carbonate. React for two hours at room temperature.
The resulting Schiff bases are reduced with 5µl of 5 M NaBH4 in 1 M NaOH
for 30 minutes at room temperature. The conjugate is purified from any
excess NaBH4 by gel filtration over Sephadex™ G25 using the column
from exp. A.14. Collect 250µl fractions and monitor for the conjugate
using Bio-Rad™ protein assay as described in experiment A.18. Pool the
fractions containing the enzyme and store at 4°C.
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A.29 AP conjugated with NaIO4 activated HRP
Add 100µl of AP stock solution (9 mg/ml) to 300µl eluate from experiment
A.27 containing the NaIO4 activated HRP. Adjust the pH to 9 with 20µl of
1 M sodium carbonate. React for two hours at room temperature.
The resulting Schiff bases are reduced with 5µl of 5 M NaBH4 in 1 M NaOH
for 30 minutes at room temperature. The conjugate is purified from any
excess NaBH4 by gel filtration over Sephadex™ G25 using the column
from exp. A.14. Collect 250µl fractions and monitor for the conjugate
using Bio-Rad™ protein assay as described in experiment A.18. Pool the
fractions containing the enzyme and store at 4°C.
A.30 Ni2+ chelate affinity chromatography of
αHRP antibody
The column prepared in experiment A.18 is used. Wash with 15 ml of
0.01 M PBS containing 0.15 M NaCl at pH 7 (binding buffer). Apply 200µl
αHRP antibody at a flow rate of 0.3 ml/min. Wash with 20 ml binding buffer
at 1 ml/min. Elute with 0.1 M NaOAc containing 0.5 M NaCl at pH 5. Collect
250µl fractions. Take a 5µl aliquot of each and add 10µl of Bio-Rad™ pro-
tein assay diluted 1:4 in H2O. Fractions containing antibody will develop a
strong blue color. Pool the fractions containing the antibody and neutralize
using a Sephadex™ G25 desalting column. Use 0.01 M sodium phosphate
containing 0.15 M NaCl at pH 7 as elution buffer. Collect 250µl fractions
and test for protein as described above. Pool the antibody containing
fractions and store at 4°C.
A.31 Ni2+ chelate pure αHRP on glass with glu-
taraldehyde
Aminosilanised cover glasses are activated in a 2.5 % glutaraldehyde so-
lution, containing 0.1 M sodium phosphate with 0.15 M NaCl, pH 7.2, for
one hour at room temperature. Wash with ice/H2O. Dilute 75µl of the
Ni2+ chelate pure αHRP (from experiment A.30) solution to a final volume
of 4.5 ml with 0.1 M sodium phosphate, 0.15 M NaCl, pH 7.2 and add this
mixture to the activated cover glasses. Allow to react for ninety minutes
at 37°C. Wash with PBS. Add 5 ml NaBH4 at a concentration of 1 mg/ml to
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reduce the resulting Schiff bases. Wash with PBS and store in 0.05 M saline
solution at 4°C.
A.32 Pepsin immobilization onto Al2O3
Take 1 g Al2O3 and wash exhaustively with 250 mM sodium acetate pH 4.5,
containing 200 mM NaCl. Dissolve 5.5 mg pepsin in 5 ml 250 mM sodium
acetate pH 4.5, containing 200 mM NaCl. Suspend the washed Al2O3 in
this solution. Incubate over night at room temperature using a magnetic
stirrer to mix.
The suspension is washed by centrifugation at 2000 rpm. Decant the su-
pernatant and add a new 10 ml portion 250 mM sodium acetate pH 4.5,
containing 200 mM NaCl. Repeat this washing procedure three times. Test
each supernatant for protein using Bio-Rad™ protein assay. The washed
Al2O3 is air dried over night at room temperature. Store at 4°C.
A.33 Lipoic acid immobilization on glass pow-
der
Prepare 15 ml 0.1 M sodium phosphate, pH 6.3 . Add 5 ml dioxane. Dis-
solve 41.2 mg lipoic acid, 43.4 mg sulfo-NHS and 38.4 mg EDC in this so-
lution. React for 30 minutes at room temperature. Adjust pH to 7.5 with
1 M Na2HPO4. Add 0.5 g aminosilanised Swarowsky™ glass powder. In-
cubate over night at room temperature.
Wash the glass powder in a suction filter, pore size 4, with:
• 5 ml DMF, 3X
• 10 ml EtOH / H2O 1:1, 2X
• 10 ml EtOH, 2X
Dry over night at 80°C.
Prepare 3 ml 50 mg/ml NaBH4 in H2O. React for 30 minutes at room temper-
ature. Wash the glass powder in a suction filter, pore size 4, with:
• 10 ml 0.1 M acetic acid, 2X
• 10 ml H2O, 2X
• 10 ml EtOH, 2X
Dry over night at room temperature.
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A.34 Affinity chromatography of antiserum from
rabbit 53
Apply 50µl antiserum from rabbit 53 on a Sephadex™ G25 desalting col-
umn (see exp. A.14). Collect 250µl fractions and monitor for protein using
Bio-Rad™ protein assay as described in experiment A.18. Pool the protein
containing fractions and apply them on a Ni2+ chelate affinity column (see
experiment A.18) at a flow rate of 0.3 ml/min. Wash with 0.05 M sodium
phosphate, pH 7, containing 0.1 M NaCl, until no more protein is eluted
(use Bio-Rad™ protein assay for this purpose).
Elute the IgG fraction with 0.05 M sodium phosphate, pH 7, containing
0.1 M NaCl and 0.01 M EDTA. Monitor for protein with Bio-Rad™ protein
assay and pool positive fractions. Store at -20°C.
A.35 PLGA on glass powder with EDC
Dissolve 600 mg PLGA in 25 ml DMSO. Prepare 15 mg EDC and 15 mg
sulfo-NHS in 1 ml H2O. Mix the two solutions and react for ten minutes
at room temperature. Add 2 g aminosilanised glass powder. Shake the
suspension for one hour at room temperature. Wash the glass powder in a
suction filter, pore size 4, with:
• 10 ml 0.1 M DMSO, 4X
• 10 ml H2O/DMSO 1:1 , 2X
• 10 ml H2O, 4X
Dry over night at room temperature.
A.36 PLGA on AP
Prepare 32µl PLGA in DMSO at a concentration of 1 mg/ml. Add 0.1 mg
EDC and activate for 30 minutes at room temperature.
Dilute 50µl AP stock solution (9 mg/ml) to 500µl with 0.1 M sodium phos-
phate pH 9. Add the activated PLGA solution and react over night at 4°C.
The conjugate is purified over a Sephadex™ G25 desalting column (see
exp. A.14). Collect 250µl fractions and monitor for protein using Bio-
Rad™ protein assay as described in experiment A.18. Pool the fractions
containing the enzyme and store at 4°C.
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A.37 Ni2+ chelate pure antiserum from rabbit 53
on glass with glutaraldehyde
Activate aminosilanised cover glasses in a 2.5% glutaraldehyde solution in
0.05 M PBS at pH 7 for one hour at room temperature. Wash with ice/H2O.
Dilute 2.5µl purified antiserum from experiment A.34 to 200µl with 0.05 M
sodium phosphate pH 7 . Add a 200µl portion to each cover glass and
incubate for one hour at room temperature. Wash with 0.05 M sodium
phosphate pH 7 and store at 4°C.
A.38 Ni2+ chelate pure antiserum from rabbit 53
on glass powder with sulfo-SMCC
Dilute 250µl purified antiserum from experiment A.34 to 500µl with PBS
containing 0.15 M NaCl, 10 mM EDTA, pH 7.2. Add 1 mg 2-mercaptoethyl-
amine and mix to dissolve. React for 90 min at 37°C.
The aminosilanised glass powder (0.6 g) is activated in 2 ml 0.1 M phos-
phate buffer containing 0.15 M NaCl, 1 mg/ml sulfo-SMCC, pH 7.2. Allow to
react for 30 min at room temperature. Wash with PBS and store wet until
the antibodies are ready for coupling.
The reduced Ni2+ chelate pure antibodies are purified from excess mercapto-
ethylamine by gel filtration over Sephadex™ G25 using the column from
exp. A.14. Elute with 0.1 M PBS containing 0.15 M NaCl, 0.01 M EDTA,
pH 7.2 at a flow rate of 1 ml/min. Collect 250µl fractions and monitor for the
antibody using Bio-Rad™ protein assay as described in experiment A.18.
Pool the antibody containing fractions, dilute to the desired volume with
PBS and add the solution immediately to the previously activated glass
powder. Incubate over night at 4°C. Wash with PBS and store in 0.05 M
saline solution at 4°C.
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Appendix B
Experimental Data and
Regression Lines
Table B.1: EtOH-silanised cover glass; AP immobilized with GA
Time (s) Extinction
20 0.045
45 0.064
70 0.078
100 0.103
130 0.122
160 0.143
190 0.163
220 0.180
250 0.208
Table B.2: 0.5 M HCl - etched 316-L; AP immobilized with GA
Time (s) Extinction
60 0.023
100 0.045
150 0.078
185 0.096
240 0.130
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Table B.3: 6 M HCl - etched 316-L; AP immobilized with GA
Time (s) Extinction
120 0.003
185 0.030
240 0.055
275 0.063
310 0.076
Table B.4: 3 % HNO3 - etched 316-L; AP immobilized with GA
Time (s) Extinction
43 0.030
80 0.050
121 0.072
165 0.096
210 0.118
247 0.139
285 0.164
Table B.5: not etched 316-L; AP immobilized with GA
Time (s) Extinction
45 0.023
85 0.023
125 0.026
155 0.028
195 0.036
240 0.037
275 0.038
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Table B.6: Sample B.1; repeated measurement
Time (s) Extinction
35 0.059
63 0.067
92 0.084
127 0.119
173 0.140
206 0.156
247 0.185
Table B.7: 0.56 ng/ml AP Standard
Time (s) Extinction
35 0.001
66 0.007
102 0.012
147 0.017
182 0.023
227 0.033
Table B.8: 1.12 ng/ml AP Standard
Time (s) Extinction
37 0.030
62 0.044
103 0.060
140 0.076
180 0.096
219 0.113
248 0.123
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Table B.9: 2.24 ng/ml AP Standard
Time (s) Extinction
41 0.035
70 0.055
112 0.082
156 0.111
187 0.131
223 0.150
253 0.164
Table B.10: 4.49 ng/ml AP Standard
Time (s) Extinction
37 0.052
74 0.109
101 0.143
131 0.179
170 0.222
211 0.267
248 0.307
Table B.11: 0.5 M HCl - etched 316-L; PEG immobilized with p-chloranil; AP immobilized
with p-chloranil
Time (s) Extinction
87 0.024
127 0.029
158 0.033
208 0.037
247 0.045
299 0.051
334 0.055
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Table B.12: 0.5 M HCl - etched 316-L; PEG immobilized with EDC, pH 5; AP immobilized
with GA
Time (s) Extinction
43 0.024
75 0.031
108 0.039
140 0.047
170 0.055
206 0.063
237 0.071
Table B.13: 6 M HCl - etched 316-L; PEG immobilized with EDC, pH 5; AP immobilized
with GA
Time (s) Extinction
41 0.021
80 0.032
111 0.038
155 0.047
185 0.055
227 0.065
253 0.073
75
Table B.14: 3 % HNO3 - etched 316-L; PEG immobilized with EDC, pH 5; AP immobilized
with GA
Time (s) Extinction
32 0.015
71 0.024
117 0.038
169 0.049
209 0.058
273 0.072
Table B.15: 0.5 M HCl - etched 316-L; PEG immobilized with EDC, pH 10; AP immobilized
with GA
Time (s) Extinction
42 0.025
75 0.03
110 0.037
156 0.048
193 0.059
224 0.067
Table B.16: 6 M HCl - etched 316-L; PEG immobilized with EDC, pH 10; AP immobilized
with GA
Time (s) Extinction
34 0.020
69 0.027
100 0.035
144 0.045
180 0.053
219 0.063
250 0.069
76
Table B.17: 3 % HNO3 - etched 316-L; PEG immobilized with EDC, pH 10; AP immobilized
with GA
Time (s) Extinction
41 0.020
78 0.030
119 0.039
156 0.048
186 0.054
218 0.061
247 0.069
Table B.18: ZrO2; AP immobilized with GA
Time (s) Extinction
28 0.020
64 0.029
94 0.034
142 0.044
183 0.053
216 0.061
246 0.067
Table B.19: Blank sample; 0.5 M HCl - etched 316-L; not silanised; PEG immobilised with
EDC, pH 5; AP immobilised with GA
Time (s) Extinction
26 0.023
64 0.025
105 0.024
184 0.025
213 0.024
77
Table B.20: 3 % HNO3 - etched 316-L; PEG immobilized with EDC, pH 5; AP immobilized
with EDC, pH 5
Time (s) Extinction
34 0.022
68 0.033
101 0.047
134 0.058
181 0.073
226 0.090
Table B.21: 3 % HNO3 - etched 316-L; PEG immobilized with EDC, pH 10; AP immobilized
with EDC, pH 10
Time (s) Extinction
32 0.018
76 0.025
115 0.034
159 0.041
200 0.050
240 0.059
Table B.22: 0.5 M HCl - etched 316-L; PEG immobilized with EDC, pH 5; AP immobilized
with EDC, pH 5
Time (s) Extinction
48 0.032
95 0.060
142 0.086
187 0.104
242 0.126
264 0.150
78
Table B.23: 0.5 M HCl - etched 316-L; PEG immobilized with EDC, pH 10; AP immobilized
with EDC, pH 10
Time (s) Extinction
59 0.022
102 0.032
133 0.044
182 0.052
224 0.063
254 0.072
Table B.24: 3 % HNO3 - etched 316-L; AP immobilized with EDC, pH 5; without immobi-
lized PEG
Time (s) Extinction
27 0.031
61 0.063
96 0.095
124 0.118
153 0.143
186 0.172
223 0.201
250 0.224
Table B.25: Biotinylated AP on avidin coated cover glass
Time (s) Extinction
35 0.106
68 0.214
97 0.294
127 0.369
166 0.459
198 0.518
79
Table B.26: Biotinylated AP on biotinylated cover glass; sample 1
Time (s) Extinction
33 0.039
62 0.045
91 0.044
136 0.064
186 0.076
Table B.27: Biotinylated AP on biotinylated cover glass; sample 2
Time (s) Extinction
30 0.033
72 0.049
103 0.056
140 0.074
172 0.084
80
Table B.28: αHRP on cover glass with GA, incubated with AP; blank 1
Time (s) Extinction
23 0.054
56 0.054
88 0.054
118 0.055
150 0.055
Table B.29: BSA on cover glass with GA, incubated with AP-HRP; blank 2
Time (s) Extinction
15 0.052
41 0.053
68 0.053
110 0.053
142 0.052
190 0.052
Table B.30: αHRP on cover glass with GA, incubated with AP-HRP; sample 1
Time (s) Extinction
28 0.057
64 0.058
97 0.061
156 0.066
203 0.072
241 0.076
280 0.079
81
Table B.31: αHRP on cover glass with GA, incubated with AP-HRP; sample 2
Time (s) Extinction
14 0.060
44 0.064
84 0.066
130 0.073
177 0.081
219 0.091
280 0.096
313 0.101
Table B.32: αHRP on cover glass with GA, incubated with AP-HRP; sample 3
Time (s) Extinction
0 0.109
27 0.113
61 0.120
90 0.122
128 0.130
158 0.133
190 0.141
230 0.148
262 0.151
Table B.33: αHRP on cover glass with GA, incubated with AP-HRP; sample 4
Time (s) Extinction
14 0.055
47 0.062
73 0.067
103 0.072
134 0.080
168 0.083
208 0.089
247 0.096
82
Table B.34: αHRP on cover glass with GA, incubated with AP-HRP; repeated measure-
ment sample 1 (B.30)
Time (s) Extinction
20 0.028
59 0.029
95 0.030
132 0.033
179 0.035
225 0.038
278 0.043
307 0.045
Table B.35: αHRP on cover glass with GA, incubated with AP-HRP; repeated measure-
ment sample 2 (B.31)
Time (s) Extinction
24 0.028
56 0.035
106 0.036
157 0.039
260 0.050
298 0.051
395 0.056
Table B.36: αHRP on cover glass with GA, incubated with AP-HRP; repeated measure-
ment sample 3 (B.32)
Time (s) Extinction
21 0.031
52 0.033
93 0.037
125 0.040
160 0.047
200 0.046
246 0.048
281 0.052
83
Table B.37: αHRP on cover glass with GA, incubated with AP-HRP; repeated measure-
ment sample 4 (B.33)
Time (s) Extinction
18 0.027
55 0.027
90 0.029
130 0.031
170 0.032
206 0.034
240 0.035
280 0.041
314 0.043
Table B.38: αHRP on cover glass with GA, incubated with AP-HRP; sample 1
Time (s) Extinction
72 0.031
106 0.037
142 0.043
175 0.048
217 0.051
260 0.063
300 0.065
Table B.39: αHRP on cover glass with GA, incubated with AP-HRP; sample 2
Time (s) Extinction
54 0.033
86 0.041
124 0.044
158 0.045
190 0.048
234 0.052
260 0.054
84
Table B.40: αHRP on cover glass with GA, incubated with AP-HRP; sample 3
Time (s) Extinction
44 0.044
76 0.047
117 0.060
151 0.066
190 0.077
223 0.089
264 0.100
301 0.106
Table B.41: αHRP on cover glass with GA, incubated with AP-HRP; sample 4
Time (s) Extinction
46 0.044
80 0.048
110 0.052
160 0.067
213 0.077
250 0.090
85
Table B.42: αHRP on cover glass with GA, incubated with AP; blank 1
Time (s) Extinction
51 0.037
130 0.038
154 0.036
206 0.040
240 0.039
280 0.041
Table B.43: αHRP on cover glass with GA, incubated with AP; blank 2
Time (s) Extinction
56 0.031
92 0.031
130 0.032
184 0.033
Table B.44: αHRP on cover glass with GA, incubated with AP-HRP; repeated measure-
ment sample 1 (B.38)
Time (s) Extinction
39 0.060
88 0.063
128 0.067
168 0.071
208 0.076
241 0.079
263 0.080
86
Table B.45: αHRP on cover glass with GA, incubated with AP-HRP; repeated measure-
ment sample 3 (B.40)
Time (s) Extinction
30 0.042
77 0.052
160 0.056
197 0.059
Table B.46: αHRP on cover glass with GA, incubated with AP-HRP; repeated measure-
ment sample 4 (B.41)
Time (s) Extinction
35 0.049
70 0.055
121 0.065
147 0.073
200 0.080
242 0.090
264 0.093
Table B.47: αHRP fragment on glass with s-SMCC, incubated with AP-HRP; sample 1
Time (s) Extinction
33 0.050
72 0.067
107 0.072
147 0.082
189 0.104
231 0.110
87
Table B.48: αHRP fragment on glass with s-SMCC, incubated with AP-HRP; sample 2
Time (s) Extinction
41 0.049
75 0.057
109 0.065
185 0.088
220 0.095
257 0.106
Table B.49: αHRP fragment on glass with s-SMCC, incubated with AP-HRP; sample 3
Time (s) Extinction
38 0.035
77 0.039
144 0.039
187 0.042
230 0.043
Table B.50: αHRP fragment on glass with s-SMCC, incubated with AP-HRP; sample 4
Time (s) Extinction
34 0.044
76 0.060
114 0.063
153 0.075
187 0.083
218 0.092
248 0.098
88
Table B.51: αHRP fragment on glass with s-SMCC, incubated with AP-HRP; sample 5
Time (s) Extinction
68 0.050
101 0.053
139 0.058
187 0.063
224 0.069
270 0.083
Table B.52: αHRP fragment on glass with s-SMCC, incubated with AP-HRP; sample 6
Time (s) Extinction
41 0.045
79 0.052
113 0.060
170 0.072
225 0.076
271 0.083
Table B.53: αHRP fragment on glass with sulfo-SMCC, incubated with AP; blank
Time (s) Extinction
29 0.034
75 0.032
117 0.033
159 0.035
214 0.032
89
Table B.54: αHRP fragment on glass with s-SMCC, incubated with AP-HRP; repeated
measurement sample 1 (B.47)
Time (s) Extinction
18 0.038
60 0.040
100 0.043
137 0.049
176 0.052
Table B.55: αHRP fragment on glass with s-SMCC, incubated with AP-HRP; repeated
measurement sample 2 (B.48)
Time (s) Extinction
30 0.032
65 0.036
95 0.040
141 0.044
180 0.052
223 0.056
Table B.56: αHRP fragment on glass with s-SMCC, incubated with AP-HRP; repeated
measurement sample 3 (B.49)
Time (s) Extinction
32 0.030
72 0.029
106 0.030
140 0.032
90
Table B.57: αHRP fragment on glass with s-SMCC, incubated with AP-HRP; repeated
measurement sample 4 (B.50)
Time (s) Extinction
30 0.032
67 0.037
103 0.041
148 0.047
230 0.055
251 0.059
Table B.58: αHRP fragment on glass with s-SMCC, incubated with AP-HRP; repeated
measurement sample 5 (B.51)
Time (s) Extinction
34 0.027
70 0.030
101 0.032
137 0.036
181 0.042
213 0.049
253 0.054
Table B.59: αHRP fragment on glass with s-SMCC, incubated with AP-HRP; repeated
measurement sample 6 (B.52)
Time (s) Extinction
24 0.022
72 0.029
100 0.032
158 0.040
190 0.044
220 0.048
254 0.051
91
Table B.60: αHRP fragment on glass with s-SMCC, incubated with AP-HRP; repeated
measurement sample 1 (B.54)
Time (s) Extinction
29 0.032
71 0.034
110 0.031
150 0.032
190 0.033
Table B.61: αHRP fragment on glass with s-SMCC, incubated with AP-HRP; repeated
measurement sample 2 (B.55)
Time (s) Extinction
36 0.030
76 0.031
114 0.032
160 0.032
202 0.034
258 0.037
310 0.038
350 0.042
400 0.044
Table B.62: αHRP fragment on glass with s-SMCC, incubated with AP-HRP; repeated
measurement sample 3 (B.56)
Time (s) Extinction
40 0.032
80 0.032
121 0.026
150 0.027
92
Table B.63: αHRP fragment on glass with s-SMCC, incubated with AP-HRP; repeated
measurement sample 4 (B.57)
Time (s) Extinction
30 0.030
67 0.033
110 0.031
159 0.032
212 0.035
280 0.035
360 0.038
426 0.042
Table B.64: αHRP fragment on glass with s-SMCC, incubated with AP-HRP; repeated
measurement sample 5 (B.58)
Time (s) Extinction
30 0.030
95 0.034
143 0.038
200 0.040
247 0.042
295 0.044
Table B.65: αHRP fragment on glass with s-SMCC, incubated with AP-HRP; repeated
measurement sample 6 (B.59)
Time (s) Extinction
24 0.026
66 0.027
120 0.028
164 0.030
220 0.032
330 0.034
380 0.040
423 0.042
466 0.044
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Abbreviations
316-L surgical stainless steel
ADCC Antibody dependent cell mediated cytotoxicity
αHRP Anti HRP antibody
AP alkaline phosphatase
BAPA Bacillus anthracis protective antigen
Biocytin -N-(+)-Biotinyl-L-lysine
BSA Bovine Serum Albumin
CD Cluster of differentiation
CD3 Part of the T cell receptor complex
CD20 Phosphoprotein expressed on the surface of mature B-cells
CD33 Trans membrane receptor expressed on cells of monocytic
myeloid lineage
CD147 Basignin (EMMPRIN), extracellular matrix
metalloproteinase inducer
CDR Complementary Determining Region
CMV Cytomegalovirus
CSGP 17-1A Cell-surface glycoprotein 17-1A
dαg Donkey anti goat antibody
DMSO Dimethyl sulfoxide
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EDC 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide
hydrochloride
EGFR Epidermal growth factor receptor
ELISA Enzyme Linked Immuno Sorbent Assay
Ep-CAM Epithelial cell adhesion molecule
EPR-effect enhanced permeability and retention effect
EtOH Ethanol
FDA Food and Drug Administration
Fv Variable fragment of an antibody
GA Glutaraldehyde
gαm-HRP Goat anti mouse antibody HRP conjugate
GD2 Disialoganglioside expressed on neuroectodermal tumours
gp-120 Glycoprotein (120 kD) on the surface of the HIV envelope .
HA Hemagglutinin
HER2 Human epidermal growth factor receptor 2 (CD 340)
HFC Hollow fibre cartridge
HRP Horseradish peroxidase
IFA Incomplete Freund’s Adjuvant
IFNγ Interferon γ
Ig Immunoglobulin
IGF-IR Insulin-like growth factor I receptor
IgG Immunoglobulin G
IL-2R β Interleukin-2 receptor β-subunit
IL-6 Interleukin-6
IL-6R Interleukin-6 Receptor
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kD Kilo Dalton
Lewis-Y Fucosyltransferase 3 (CD174)
M Molar; mol/L
mαHA Mouse anti HA antibody
mAb monoclonal antibody
Mr Molecular weight
MUC-1 Mucin 1, membrane bound glycosylated phosphoprotein
(CD227)
NHS N-Hydroxysuccinimide
OP Oligopeptide
PBS Phosphate buffer saline
PEG Polyethylene glycol
PCR Polymerase chain reaction
PTHrP Parathyroid hormone-related protein
PSMA Prostate specific membrane antigen
RAAG12 N-linked carbohydrate antigen expressed on solid organ
cancers
rαm-HRP Rabbit anti mouse antibody HRP conjugate
scFv single chain Fv fragment
SELEX systemic evolution of ligands by exponential enrichment
SMCC Succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-
carboxylate
s-NHS N-hydroxysulfosuccinimide
SPION Super Paramagnetic Iron Oxide Nano Particle
TBS TRIS buffer saline
TCF Tissue culture flask
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TGF β1 Transforming growth factor β-1
TMB 3,3’,5,5’-Tetramethylbenzidine
TNF α Tumour necrosis factor α
Tris Tris(hydroxymethyl)aminomethane
VEGF Vascular endothelial growth factor
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